Document:

EX-4.2

 Exhibit 4.2 

INVESTORS’ RIGHTS AGREEMENT 

THIS INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of April 6, 2018 by and among Allogene
Therapeutics, Inc. a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor.” 

RECITALS: 

WHEREAS, the Company and the Investors are parties to that certain Preferred Stock Purchase Agreement of even date herewith (the
“Purchase Agreement”); and 
 WHEREAS, the Company and Pfizer Inc. (“Pfizer”) are parties to an
Asset Contribution Agreement dated April 2, 2018 (the “ACA”) providing for the purchase and sale of certain Pfizer assets in exchange for shares of Series A-1 Preferred Stock; and

 WHEREAS, in order to induce the Company to enter into the Purchase Agreement, to induce the Investors to invest funds in the
Company pursuant to the Purchase Agreement, and to induce Pfizer to enter into the ACA and consummate the transactions contemplated thereby, the Investors and the Company hereby agree that this Agreement shall govern the rights of the Investors to
cause the Company to register shares of Common Stock issuable to the Investors, to receive certain information from the Company, and to participate in future equity offerings by the Company, and shall govern certain other matters as set forth in
this Agreement; 
 NOW, THEREFORE, the parties hereby agree as follows: 

1.    Definitions. For purposes of this Agreement: 

1.1    “Affiliate” means, with respect to any specified Person, any other Person who,
directly or indirectly, controls, is controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer, director or trustee of such Person, or any venture capital fund or
registered investment company now or hereafter existing that is controlled by one or more general partners, managing members or investment adviser of, or shares the same management company or investment adviser with, such Person. 

1.2    “Board of Directors” means the board of directors of the Company. 

1.3    “Certificate of Incorporation” means the Company’s Amended and Restated
Certificate of Incorporation, as amended and/or restated from time to time. 

1.4    “Class A Director” means any director of the
Company that the holders of record of the Preferred Stock are entitled to elect, exclusively and as a separate class or series of Preferred Stock, in each case pursuant to the Certificate of Incorporation. 

1.5    “Common Stock” means shares of the Company’s common stock, par value $0.001
per share. 

 1.6    “Competitor” means a Person,
other than an Investor, engaged, directly or indirectly (including through any partnership, limited liability company, corporation, joint venture or similar arrangement (whether now existing or formed hereafter)), in the business of
discovering, developing or commercializing pharmaceutical products for use in the fields of oncology or cell-based therapies, but shall not include any financial investment firm or collective investment vehicle that, together with its Affiliates,
holds less than 20% of the outstanding equity of any Competitor and does not, nor do any of its Affiliates, have a right to designate any members of the board of directors of any Competitor. 

1.7    “Damages” means any loss, damage, claim or liability (joint or several) to which a
party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon: (i) any untrue
statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an
omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its
agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

1.8    “Derivative Securities” means any securities or rights convertible into, or
exercisable or exchangeable for (in each case, directly or indirectly), Common Stock, including options and warrants. 

1.9    “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules
and regulations promulgated thereunder. 
 1.10    “Excluded Registration” means:
(i) a registration relating to the sale or grant of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, equity incentive or similar plan; (ii) a registration relating to the issuance of
securities in an SEC Rule 145 transaction; (iii) a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable
Securities; or (iv) a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered. 

1.11    “FOIA Party” means a Person, other than an Investor, that, in the reasonable
determination of the Board of Directors, may be subject to, and thereby required to disclose non-public information furnished by or relating to the Company under, the Freedom of Information Act, 5 U.S.C. 552
(“FOIA”), any state public records access law, any state or other jurisdiction’s laws similar in intent or effect to FOIA, or any other similar statutory or regulatory requirement. 

  
 2 

 1.12    “Form S-1” means such form under the Securities Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 

1.13    “Form S-3” means such form under
the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits forward incorporation of substantial information by reference to other documents filed by the Company
with the SEC. 
 1.14    “GAAP” means generally accepted accounting principles in the
United States as in effect from time to time. 
 1.15    “Holder” means any holder of
Registrable Securities who is a party to this Agreement. 
 1.16    “Immediate Family
Member” means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including, adoptive relationships, of a natural
person referred to herein. 
 1.17    “Initiating Holders” means, collectively, Holders
who properly initiate a registration request under this Agreement. 
 1.18    “IPO”
means the Company’s first underwritten public offering of its Common Stock under the Securities Act. 

1.19    “Major Investor” means any Investor that, individually or together with such
Investor’s Affiliates, holds at least 285,207 shares of Registrable Securities, (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof) and for so long as it
or its Affiliates hold Registrable Securities, Seaview Trust and Belldegrun Family Trust. 

1.20    “New Securities” means, collectively, equity securities of the Company, whether or
not currently authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. 

1.21    “Person” means any individual, corporation, partnership, trust, limited liability
company, association or other entity. 
 1.22    “Preferred Stock” means, collectively,
shares of the Company’s Series A Preferred Stock and Series A-1 Preferred Stock. 

1.23    “Registrable Securities” means: (i) the Common Stock issuable or issued upon
conversion of the Preferred Stock; (ii) any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company, acquired by the
Investors after the date hereof; and (iii) any Common Stock 

  
 3 

 
issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in
replacement of, the shares referenced in clauses (i) and (ii) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned
pursuant to Subsection 6.1, and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Subsection 2.13 of this Agreement. 

1.24    “Registrable Securities then outstanding” means the number of shares determined by
adding the number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable
Securities. 
 1.25    “Restricted Securities” means the securities of the Company
required to be notated with the legend set forth in Subsection 2.12(b) hereof. 

1.26    “SEC” means the United States Securities and Exchange Commission. 

1.27    “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act.

 1.28    “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities
Act. 
 1.29    “Securities Act” means the Securities Act of 1933, as amended, and the
rules and regulations promulgated thereunder. 
 1.30    “Selling Expenses” means all
underwriting discounts, selling commissions, and stock transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne
and paid by the Company as provided in Subsection 2.6. 

1.31    “Series A Preferred Stock” means shares of the Company’s Series A Preferred
Stock, par value $0.001 per share. 
 1.32    “Series A-1 Preferred Stock” means shares
of the Company’s Series A-1 Preferred Stock, par value $0.001 per share. 
 2.    Registration Rights. The
Company covenants and agrees as follows: 
 2.1    Demand Registration. 

(a)    Form S-1 Demand. If at any time after the earlier of (i) three
years after the date of this Agreement or (ii) 180 days after the effective date of the registration statement for the IPO, the Company receives a request from holders of at least 51% of the Registrable

  
 4 

 
Securities then outstanding (but excluding for the specific purpose of this voting threshold shares of Common Stock issued or issuable solely as a result of the provisions of Article Fourth
Section B(4.11) of the Certificate of Incorporation) that the Company file a Form S-1 registration statement with respect to the sale of Registrable Securities for which the anticipated aggregate
offering price, net of Selling Expenses, would exceed $20 million), then the Company shall (x) within 10 days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the
Initiating Holders; and (y) as soon as practicable, and in any event within 60 days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the
Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice
given by each such Holder to the Company within 20 days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3. 

(b)    Form S-3 Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of at least 30% of the Registrable Securities then outstanding (but excluding for the specific purpose of this voting threshold shares of
Common Stock issued or issuable solely as a result of the provisions of Article Fourth Section B(4.11) of the Certificate of Incorporation) that the Company file a Form S-3 registration statement with respect
to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $2 million, then the Company shall (i) within 10 days after the date such request is given, give a
Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within 45 days after the date such request is given by the Initiating Holders, file a Form
S-3 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be
included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within 20 days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.1(c) and
2.3. 
 (c)    Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a
registration pursuant to this Subsection 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Board of Directors it would be materially detrimental to the Company and its
stockholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would: (i) materially interfere with a
significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential;
or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or
effectiveness thereof shall be tolled correspondingly, for a period of not more than 60 days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than once in any
12-month period; and provided further that the Company shall not register any securities for its own account or that of any other stockholder during such 60-day period, other than pursuant to a
registration relating to the sale or 

  
 5 

 
grant of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, equity incentive or similar plan; a registration on any form that does not include
substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or a registration in which the only Common Stock being registered is Common Stock issuable upon
conversion of debt securities that are also being registered. 
 (d)    The Company shall not be obligated to effect,
or to take any action to effect, any registration pursuant to Subsection 2.1(a): (i) during the period that is 90 days before the Company’s good faith estimate of the date of filing of, and ending on a date that is 180 days after
the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company has
effected two registrations pursuant to Subsection 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3
pursuant to a request made pursuant to Subsection 2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(b): (i) during the period that is 30 days before the
Company’s good faith estimate of the date of filing of, and ending on a date that is 60 days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable
efforts to cause such registration statement to become effective; or (ii) if the Company has effected two registrations pursuant to Subsection 2.1(b) within the 12-month period immediately preceding the date of such request. A
registration shall not be counted as “effected” for purposes of this Subsection 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw
their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to Subsection 2.6, in which case such withdrawn registration statement shall be
counted as “effected” for purposes of this Subsection 2.1(d); provided, that if such withdrawal is during a period the Company has deferred taking action pursuant to Subsection 2.1(c), then the Initiating
Holders may withdraw their request for registration and such registration will not be counted as “effected” for purposes of this Subsection 2.1(d). 

2.2    Company Registration. If the Company proposes to register (including, for this purpose, a
registration effected by the Company for stockholders other than the Holders) any of its securities under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded Registration), the
Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within 20 days after such notice is given by the Company, the Company shall, subject to the provisions of Subsection
2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this
Subsection 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be
borne by the Company in accordance with Subsection 2.6. 

  
 6 

 2.3    Underwriting Requirements. 

(a)    If, pursuant to Subsection 2.1, the Initiating Holders intend to distribute the Registrable
Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Subsection 2.1, and the Company shall include such information in the Demand Notice. The
underwriter(s) will be selected by the Initiating Holders, subject only to the reasonable approval of the Board of Directors. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be
conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through
such underwriting shall (together with the Company as provided in Subsection 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this
Subsection 2.3, if the managing underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of
Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating
Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number
of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. 

(b)    In connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant
to Subsection 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon between the Company and its
underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable Securities, requested by
stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the Company
shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the
underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among the selling Holders in
proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. Notwithstanding the foregoing, in no event shall
(i) the number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or (ii) the number of Registrable
Securities included in the offering be reduced below 30% of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the
determination described above and no other stockholder’s 

  
 7 

 
securities are included in such offering. For purposes of the provision in this Subsection 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability
company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any
trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable
Securities owned by all Persons included in such “selling Holder,” as defined in this sentence. 
 (c)    For
purposes of Subsection 2.1, a registration shall not be counted as “effected” if, as a result of an exercise of the underwriter’s cutback provisions in Subsection 2.3(a), fewer than 50% of the total number of Registrable
Securities that Holders have requested to be included in such registration statement are actually included. 

2.4    Obligations of the Company. Whenever required under this Section 2
to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a)    prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its
commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period
of up to 120 days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that: (i) such 120-day period shall be extended for a period of time equal to the period
the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such 120-day period shall be extended to be a one-year period, if necessary, to keep the registration statement effective until all such Registrable Securities are sold; 

(b)    prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus
used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

(c)    furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as
required by the Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d)    use its commercially reasonable efforts to register and qualify the securities covered by such registration
statement under such other securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do
business or to file a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

  
 8 

 (e)    in the event of any underwritten public offering, enter into and
perform its obligations under an underwriting agreement, in usual and customary form, with the underwriter(s) of such offering; 

(f)    use its commercially reasonable efforts to cause all such Registrable Securities covered by such registration
statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

(g)    provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and
provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; 

(h)    promptly make available for inspection by the selling Holders, any managing underwriter(s) participating in any
disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of
the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or
advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

(i)    notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration
statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 

(j)    after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the
Company amend or supplement such registration statement or prospectus. 
 In addition, the Company shall ensure that, at all times after any
registration statement covering a public offering of securities of the Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under
Rule 10b5-1 of the Exchange Act. 
 2.5    Furnish
Information. It shall be a condition precedent to the obligations of the Company to effect any registration statement pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such
Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s
Registrable Securities. 

  
 9 

 2.6    Expenses of Registration. All expenses
(other than Selling Expenses) incurred in connection with registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees
and disbursements of counsel for the Company; and the reasonable fees and disbursements of one counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided,
however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Subsection 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority
of the Registrable Securities to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a
majority of the Registrable Securities agree to forfeit their right to one registration pursuant to Subsections 2.1(a) or 2.1(b), as the case may be; provided further that if, at the time of such withdrawal, the
Holders shall have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of
such information then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to Subsections 2.1(a) or 2.1(b). All Selling Expenses relating to Registrable Securities
registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf. 

2.7    Delay of Registration. No Holder shall have any right to obtain or seek an injunction
restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8    Indemnification. If any Registrable Securities are included in a registration statement under
this Section 2: 
 (a)    To the extent permitted by law, the Company will indemnify and hold
harmless each selling Holder and its Affiliates, and the partners, members, officers, directors, and stockholders of each such Holder and its Affiliates; legal counsel and accountants for each such Holder and its Affiliates; any underwriter (as
defined in the Securities Act) for each such Holder and its Affiliates; and each Person, if any, who controls or is alleged to control such Holder, its Affiliates or underwriter within the meaning of the Securities Act or the Exchange Act, against
any Damages, and the Company will pay to each such Holder, its Affiliates, underwriter, controlling Person, or other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any
claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Subsection 2.8(a) shall not apply to amounts paid in settlement of any
such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon
actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of and relating to any such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection with
such registration. 

  
 10 

 (b)    To the extent permitted by law, each selling Holder, severally
and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls or is alleged to control the Company within the meaning of
the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other
Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of and relating to such
selling Holder expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating
or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Subsection 2.8(b) shall not apply to amounts paid in
settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by
any Holder by way of indemnity or contribution under Subsections 2.8(b) and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful
misconduct by such Holder. 
 (c)    Promptly after receipt by an indemnified party under this Subsection 2.8
of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying
party under this Subsection 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate
jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other
indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if such indemnified party reasonably determines that
representation by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give
notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Subsection 2.8, to the extent that such failure
materially prejudices the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this
Subsection 2.8. 
 (d)    To provide for just and equitable contribution to joint liability under the Securities
Act in any case in which either: (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Subsection 2.8 but it is judicially 

  
 11 

 
determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such
indemnification may not be enforced in such case, notwithstanding the fact that this Subsection 2.8 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto
for which indemnification is provided under this Subsection 2.8, then, and in each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution
from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage,
liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or
allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to
information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case (x) no Holder will be required to contribute any amount in excess of the public offering price of all such
Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to
contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this Subsection 2.8(d), when combined with the amounts paid
or payable by such Holder pursuant to Subsection 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder. 

(e)    Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in
the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(f)    Unless otherwise expressly superseded by an underwriting agreement entered into in connection with the
underwritten public offering, the obligations of the Company and Holders under this Subsection 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and
otherwise shall survive the termination of this Agreement. 
 2.9    Reports Under Exchange Act.
With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a
registration on Form S-3, the Company shall: 
 (a)    make and keep available
adequate current public information, as those terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; 

  
 12 

 (b)    use commercially reasonable efforts to file with the SEC in a
timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

(c)    furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to
the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the
IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form
S-3 (at any time after the Company so qualifies) and (ii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any
such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies
to use such form). 
 2.10    Limitations on Subsequent Registration Rights. From and after the
date of this Agreement, the Company shall not, without the prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the
Company that would: (i) provide to such holder or prospective holder the right to include securities in any registration on other than a subordinate basis after all Holders have had the opportunity to include in the registration and offering
all shares of Registrable Securities that they wish to so include; (ii) allow such holder or prospective holder to include such securities in any registration unless, under the terms of such agreement, such holder or prospective holder may
include such securities in any such registration only to the extent that the inclusion of such securities will not reduce the number of the Registrable Securities of the Holders that are included in any manner; or (iii) allow such holder or
prospective holder to initiate a demand for registration of any securities held by such holder or prospective holder. 

2.11    “Market Stand-off”
Agreement. Each Holder hereby agrees, if requested by the managing underwriter, that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the
registration by the Company for its own behalf of shares of its Common Stock or any other equity securities under the Securities Act on a registration statement on Form S-1, and ending on the date specified by the Company and the managing
underwriter (such period not to exceed 180 days in the case of the IPO): (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to
purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock held immediately before the
effective date of the registration statement for such offering, or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether
any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in 

  
 13 

 
cash, or otherwise. The foregoing provisions of this Subsection 2.11 shall: (x) apply only to the IPO; (y) not apply to the sale of any shares to an underwriter pursuant
to an underwriting agreement, or the transfer of any shares to any trust for the direct or indirect benefit of the Holder or the immediate family of the Holder, provided that the trustee of the trust agrees to be bound in writing by the
restrictions set forth herein, and provided further that any such transfer shall not involve a disposition for value; and (z) be applicable to the Holders only if all officers, directors, and stockholders individually owning more
than 1% of the Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding Class A Preferred Stock) are subject to the same restrictions. The underwriters in connection with such registration
are intended third-party beneficiaries of this Subsection 2.11 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further
agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Subsection 2.11 or that are necessary to give further effect thereto. Any discretionary
waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Company stockholders that are subject to such agreements, based on the number of shares subject to such
agreements. 
 2.12    Restrictions on Transfer. 

(a)    The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the
Company shall not recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure
compliance with the provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities
subject to the provisions and upon the conditions specified in this Agreement. 
 (b)    Each certificate, instrument,
or book entry representing (i) the Preferred Stock, (ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend,
recapitalization, merger, consolidation, or similar event, shall (unless otherwise permitted by the provisions of Subsection 2.12(c)) be notated with a legend substantially in the following form: 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES
MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER,
A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 

  
 14 

 The Holders consent to the Company making a notation in its records and giving instructions
to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Subsection 2.12. 

The foregoing legend shall be removed from the certificates representing any Restricted Securities, at the request of the holder thereof, at
such time as (a) a period of at least one year, as determined in accordance with paragraph (d) of SEC Rule 144, has elapsed since the later of the date the Restricted Securities were acquired from the Company or an affiliate of the
Company, and (b) the Restricted Securities become eligible for resale pursuant to SEC Rule 144(b)(1)(i). 

(c)    The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects
with the provisions of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed
transaction, the Holder thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in
sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder’s expense by either: (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the
Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or
transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to
the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such
Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter: (x) in any transaction in compliance with SEC Rule 144; or
(y) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration; provided that each transferee agrees in writing to be subject to the terms of this Subsection 2.12.
Each certificate, instrument, or book entry representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in
Subsection 2.12(b), except that such certificate instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish
compliance with any provisions of the Securities Act. 
 2.13    Termination of Registration
Rights. The right of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Subsections 2.1 or 2.2 shall terminate upon the earliest to occur of: 

(a)    the closing of a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation; 

  
 15 

 (b)    such time after consummation of the IPO as Rule 144 or another
similar exemption under the Securities Act is available for the sale of all of such Holder’s shares without limitation during a three-month period without registration; or 

(c)    the fifth anniversary of the IPO. 

3.    Information and Observer Rights. 

3.1    Delivery of Financial Statements. The Company shall deliver to each Major Investor: 

(a)    as soon as practicable, but in any event within 120 days after the end of each fiscal year of the Company:
(i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and a comparison between (x) the actual amounts as of and for such fiscal year and (y) the comparable amounts for the
prior year and as included in the Budget (as defined in Subsection 3.1(d)) for such year, with an explanation of any material differences between such amounts and a schedule as to the sources and applications of funds for such year, and
(iii) a statement of stockholders’ equity as of the end of such year, all such financial statements audited and certified by independent public accountants of nationally recognized standing selected by the Company; 

(b)    as soon as practicable, but in any event within 45 days after the end of each of the first three quarters of each
fiscal year of the Company, unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet and a statement of stockholders’ equity as of the end of such fiscal quarter, all prepared in accordance with GAAP
(except that such financial statements may (i) be subject to normal year-end audit adjustments; and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

(c)    as soon as practicable, but in any event within 45 days after the end of each of the first three quarters of each
fiscal year of the Company, a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock outstanding at the end of the period, the Common Stock issuable
upon conversion or exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock options not yet issued but
reserved for issuance, if any, all in sufficient detail as to permit the Major Investors to calculate their respective percentage equity ownership in the Company, and certified by the chief financial officer or chief executive officer of the Company
as being true, complete, and correct; 
 (d)    as soon as practicable before the end of each fiscal year, a budget and
business plan for the next fiscal year (collectively, the “Budget”), approved by the Board of Directors, including balance sheets, income statements, and statements of cash flow for such months and, promptly after prepared, any
other budgets or revised budgets prepared by the Company; and 

  
 16 

 (e)    with respect to the financial statements called for in
Subsection 3.1(a) and Subsection 3.1(b), an instrument executed by the chief financial officer and chief executive officer of the Company certifying that such financial statements were prepared in accordance with GAAP consistently
applied with prior practice for earlier periods (except as otherwise set forth in Subsection 3.1(b) and fairly present the financial condition of the Company and its results of operation for the periods specified therein. 

If, for any period, the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period
the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. 

Notwithstanding anything else in this Subsection 3.1 to the contrary, the Company may cease providing the information set forth in this
Subsection 3.1 during the period starting with the date 30 days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply with the SEC rules applicable
to such registration statement and related offering; provided that the Company’s covenants under this Subsection 3.1 shall be reinstated at such time as the Company is no longer actively employing its commercially reasonable
efforts to cause such registration statement to become effective. 
 3.2    Inspection. The
Company shall permit each Major Investor, at such Major Investor’s expense, to visit and inspect the Company’s properties; examine its books of account and records; and discuss the Company’s affairs, finances, and accounts with its
officers, during normal business hours of the Company as may be reasonably requested by the Major Investor; provided, however, that the Company shall not be obligated pursuant to this Subsection 3.2 to provide access to any
information that it reasonably and in good faith considers to be a trade secret or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

3.3    Observer Rights. As long as Gilead Sciences, Inc., or a subsidiary thereof,
(“Gilead”) owns not less than 50% of the shares of Series A Preferred Stock it is purchasing under the Purchase Agreement (or an equivalent amount of Common Stock issued upon conversion thereof), the Company shall invite a
representative of Gilead to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its
directors at the same time and in the same manner as provided to such directors; provided, however, that at the Company’s request, the Company and such representative shall enter into a confidentiality agreement in customary form
reasonably acceptable to Gilead; provided further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if the Company reasonably and in good faith
believes that access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest; and provided further
that such representative shall not be any individual affiliated directly with Gilead’s business activities in the field of oncology or cell-based therapy. 

  
 17 

 3.4    Termination of Information and Observer
Rights. The covenants set forth in Subsection 3.1, Subsection 3.2 and Subsection 3.3 shall terminate and be of no further force or effect: (i) immediately before the consummation of the IPO; (ii) when the Company
first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act; or (iii) upon the closing of a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation, whichever
event occurs first. 
 3.5    Confidentiality. Each Investor agrees that such Investor will keep
confidential and will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the
Company’s intention to file a registration statement), unless such confidential information: (a) is known or becomes known to the public in general (other than as a result of a breach of this Subsection 3.5 by such Investor); (b) is
or has been independently developed or conceived by such Investor without use of the Company’s confidential information; or (c) is or has been made known or disclosed to such Investor by a third party without a breach of any obligation of
confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information: (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary
to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by the provisions of this
Subsection 3.5; (iii) to any existing or prospective Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, provided that such existing or prospective Investor
informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information; or (iv) as may otherwise be required by law, regulation, rule, court order or subpoena (including of any
securities exchange or market), provided that such Investor promptly, to the extent practicable, notifies the Company of such disclosure and furnishes only that portion of the confidential information that is legally compelled or is otherwise
legally required to be disclosed, as reasonably determined by such Investor’s legal counsel. For avoidance of doubt, notwithstanding the notice and other obligations in (iv), the Company acknowledges and agrees that The Regents of the
University of California (the “UC”) is subject to the California Public Records Act (Cal. Govt. Code §6250 et. seq. (the “CPRA”)), which provides generally that all records relating to a public agency’s
business are open to public inspection and copying unless exempted under the CPRA, and that if the UC is required to make disclosures thereunder (as reasonably determined by the UC’s legal counsel), the UC may do so without further obligations
to the Company. 
 4.    Rights to Future Stock Issuances. 

4.1    Right of First Offer. Subject to the terms and conditions of this Subsection 4.1 and
applicable securities laws, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor. A Major Investor shall be entitled to apportion the right of first offer hereby
granted to it in such proportions as it deems appropriate, among: (i) itself, (ii) its Affiliates and (iii) its beneficial interest holders, such as limited partners, members or any other Person having

  
 18 

 
“beneficial ownership,” as such term is defined in Rule 13d-3 promulgated under the Exchange Act, of such Major Investor (“Investor
Beneficial Owners”); provided that each such Affiliate or Investor Beneficial Owner: (x) is not a Competitor or FOIA Party, unless such party’s purchase of New Securities is otherwise consented to by the Board of
Directors, (y) agrees to enter into this Agreement and each of the Voting Agreement and Right of First Refusal and Co-Sale Agreement of even date herewith among the Company, the Investors and the other
parties named therein, as an “Investor” under each such agreement (provided that any Competitor or FOIA Party shall not be entitled to any rights as a Major Investor under Subsections 3.1, 3.2, 3.3 and
4.1 hereof), and (z) agrees to purchase at least such number of New Securities as are allocable hereunder to the Major Investor holding the fewest number of Preferred Stock and any other Derivative Securities. 

(a)    The Company shall give notice (the “Offer Notice”) to each Major Investor, stating (i) its
bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities. 

(b)    By notification to the Company within 20 days after the Offer Notice is given, each Major Investor may elect to
purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock then held by such Major Investor (including all shares of Common
Stock then issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Investor bears to the total Common Stock of the Company then outstanding
(assuming (i) full conversion and/or exercise, as applicable, of all Preferred Stock and any other Derivative Securities then outstanding and (ii) excluding unallocated stock reserved under the Company’s equity incentive plan as then
in effect). At the expiration of such 20-day period, the Company shall promptly notify each Major Investor that elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of any other Major
Investor’s failure to do likewise. During the ten-day period commencing after the Company has given such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of
shares specified above, up to that portion of the New Securities for which Major Investors were entitled to subscribe but that were not subscribed for by the Major Investors which is equal to the proportion that the Common Stock issued and held, or
issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of Preferred Stock and any other Derivative Securities then held, by such Fully Exercising Investor bears to the Common Stock issued and held, or issuable (directly or
indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale
pursuant to this Subsection 4.1(b) shall occur within the later of 90 days of the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to Subsection 4.1(c). 

(c)    If all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in
Subsection 4.1(b), the Company may, during the 90-day period following the expiration of the periods provided in Subsection 4.1(b), offer and sell the remaining unsubscribed portion of such New
Securities to any Person or Persons at a price not less 

  
 19 

 
than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within such
period, or if such agreement is not consummated within 30 days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Investors in accordance
with this Subsection 4.1. 
 (d)    The right of first offer in this Subsection 4.1 shall not be
applicable to: (i) Exempted Securities (as defined in the Certificate of Incorporation), and (ii) shares of Common Stock issued in the IPO. 

4.2    Termination. The covenants set forth in Subsection 4.1 shall terminate and be of no
further force or effect: (i) immediately before the consummation of the IPO; or (ii) upon the closing of a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation, whichever event occurs first. 

5.    Additional Covenants. 

5.1    Insurance. The Company shall obtain, within 90 days of the date hereof, from financially sound and reputable
insurers Directors and Officers liability insurance in an amount and on terms and conditions satisfactory to the Board of Directors, and will use commercially reasonable efforts to cause such insurance policies to be maintained until such time as
the Board of Directors determines that such insurance should be discontinued. Notwithstanding any other provision of this Section 5.1 to the contrary, for so long as any Class A Director is serving on the Board of
Directors, the Company shall not cease to maintain a Directors and Officers liability insurance policy in an amount of at least $3,000,000 at all times prior to the initiation of clinical trials by the Company and at least $5,000,000 at all times
following the initiation of clinical trials by the Company, and the Company shall annually, within 120 days after the end of each fiscal year of the Company, deliver to the Investors a certification that such a Directors and Officers liability
insurance policy remains in effect. 
 5.2    Employee Agreements. The Company will cause each Person now or
hereafter employed by it or by any subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure and proprietary rights
assignment agreement in a customary form reasonably acceptable to the Investors. In addition, the Company shall not amend, modify, terminate, waive, or otherwise alter, in whole or in part, any of the above-referenced agreements or any restricted
stock agreement between the Company and any employee, without the consent of a majority of the Class A Directors. 

5.3    Employee Stock. Unless otherwise approved unanimously by the Board of Directors, all future
equity-based compensation awards granted to employees or consultants shall be granted with an exercise price equal to the fair value of Common Stock on such date (as determined by a 409A valuation) in the form of stock options, and shall provide for
vesting of such options over a four-year period, with the first 25% of such shares vesting no earlier than the first anniversary of the grant date, and with the remaining shares vesting in equal monthly installments over the following 36 months
(subject to double-trigger vesting acceleration in full upon a change 

  
 20 

 
of control of the Company). Additionally, all such awards shall provide for a market stand-off provision substantially similar to that in Subsection
2.11. Without the prior unanimous approval by the Board of Directors, the Company shall not amend, modify, terminate, waive or otherwise alter, in whole or in part, any stock purchase, stock restriction or option agreement with any existing
employee or service provider if such amendment would cause it to be inconsistent with this Subsection 5.3. 

5.4    Board Matters. Unless otherwise determined by the vote of a majority of the directors then in office, the
Board of Directors shall meet at least quarterly in accordance with an agreed-upon schedule. The Company shall reimburse the directors for all reasonable out-of-pocket
travel expenses incurred (consistent with the Company’s travel policy) in connection with attending meetings of the Board of Directors. The Company shall cause to be established, as soon as practicable after such request, and will maintain, an
audit and compensation committee, each of which shall consist solely of non-management directors. Other than with respect to customary audit and compensation committees of the Board of Directors, each non-employee director shall be entitled in such person’s discretion to be a member of any committee of the Board of Directors; provided that no such committee shall be required to have more than three
members, and that, subject to the next sentence, membership of any such committee shall be determined by consensus of the then-serving directors as a group; and provided further that, notwithstanding the foregoing, each non-employee director shall also be entitled in such person’s discretion to participate in meetings of any committee of the Board of Directors in a non-voting observer
capacity, and, in this respect, shall be provided with copies of all notices, minutes, consents, and other materials provided to the members of such committee(s) at the same time and in the same manner as provided to such members. Each committee of
the Board of Directors shall include at least one Class A Director (with the Class A Director(s) serving on such committees to be determined by consensus of the Class A Directors as a group). The Board of Directors shall adopt
customary delegations of authority for management promptly (but in any event within 90 days) following the Initial Closing (as defined in the Purchase Agreement). 

5.5    Successor Indemnification. If the Company or any of its successors or assignees consolidates with or merges
into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the
obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company’s Bylaws, the Certificate of Incorporation,
or elsewhere, as the case may be. 
 5.6    Expenses of Counsel. In the event of a transaction which is a Sale
of the Company (as defined in the Voting Agreement of even date herewith among the Investors, the Company and the other parties named therein), the reasonable fees and disbursements of one counsel for the Major Investors (“Investor
Counsel”), in their capacities as stockholders, shall be borne and paid by the Company. At the outset of considering a transaction which, if consummated would constitute a Sale of the Company, the Company shall obtain the ability to share
with the Investor Counsel (and such counsel’s clients) and shall share the confidential information (including, without limitation, the initial and all subsequent drafts of memoranda of understanding, letters of intent and other transaction
documents and related non-compete, employment, consulting 

  
 21 

 
and other compensation agreements and plans) pertaining to and memorializing any of the transactions which, individually or when aggregated with others would constitute the Sale of the Company.
The Company shall be obligated to share (and cause the Company’s counsel and investment bankers to share) such materials when distributed to the Company’s executives and/or any one or more of the other parties to such transaction(s). In
the event that Investor Counsel deems it appropriate, in its reasonable discretion, to enter into a joint defense agreement or other arrangement to enhance the ability of the parties to protect their communications and other reviewed materials under
the attorney client privilege, the Company shall, and shall direct its counsel to, execute and deliver to Investor Counsel and its clients such an agreement in form and substance reasonably acceptable to Investor Counsel. In the event that one or
more of the other party or parties to such transactions require the clients of Investor Counsel to enter into a confidentiality agreement and/or joint defense agreement in order to receive such information, then the Company shall share whatever
information can be shared without entry into such agreement and shall, at the same time, in good faith work expeditiously to enable Investor Counsel and its clients to negotiate and enter into the appropriate agreement(s) without undue burden to the
clients of Investor Counsel. 
 5.7    Right to Conduct Activities. The Company hereby agrees and acknowledges
that TPG Carthage Holdings, L.P. and The Rise Fund Carthage, L.P. (collectively, “TPG”) (together with its Affiliates) is a professional investment organization, Pfizer (together with its Affiliates), Gilead (together with
its Affiliates) and the UC (together with its Affiliates) are also in the business of making investments in third parties, and as such each of TPG, Pfizer, Gilead and UC review the business plans and related proprietary information of many
enterprises, some of which may compete directly or indirectly with the Company’s business (as currently conducted or as currently propose to be conducted). The Company hereby agrees that, to the extent permitted under applicable law, TPG
(and its Affiliates) Pfizer (and its Affiliates), Gilead (and its Affiliates) and UC (and its Affiliates) shall not be liable to the Company for any claim arising out of, or based upon: (i) the investment by TPG (or its Affiliates), Pfizer (or
its Affiliates), Gilead (or its Affiliates) or UC (or its Affiliates) in any entity competitive with the Company, or (ii) actions taken by any partner, officer, employee or other representative of TPG (or its Affiliates), Pfizer (or its
Affiliates), Gilead (or its Affiliates) or UC (or its Affiliates) to assist any such competitive company, whether or not such action was taken as a member of the board of directors of such competitive company or otherwise, and whether or not such
action has a detrimental effect on the Company; provided, however, that the foregoing shall not relieve (x) any of the Investors from liability associated with the unauthorized disclosure of the Company’s confidential information obtained
pursuant to this Agreement, or (y) any director or officer of the Company from any liability associated with his or her fiduciary duties to the Company. 

5.8    FCPA Compliance. The Company shall not, and shall not permit any of its subsidiaries and Affiliate or any
of its or their respective directors, officers, managers, employees, independent contractors, representatives or agents (collectively, “Representatives”) to, promise, authorize or make any payment to, or otherwise contribute any
item of value to, directly or indirectly, any non-U.S. government official, in each case, in violation of the U.S. Foreign Corrupt Practices Act, as amended (“FCPA”) or any other applicable
anti-bribery or anti-corruption law. The Company shall, and shall cause each of its subsidiaries and Affiliates to, cease all of its or their respective activities, as well as remediate any actions taken by the Company, its subsidiaries

  
 22 

 
or Affiliates or any of its or their respective Representatives in violation of the FCPA or any other applicable anti-bribery or anti-corruption law. The Company shall, and shall cause each of
its Affiliates and subsidiaries to, maintain systems or internal controls (including, but not limited to, accounting systems, purchasing systems and billing systems) to ensure compliance with the FCPA or any other applicable anti-bribery or
anti-corruption law. 
 5.9    Termination of Covenants. The covenants set forth in this
Section 5, except for Subsections 5.5, 5.6 and 5.7, shall terminate and be of no further force or effect: (i) immediately before the consummation of the IPO, (ii) when the Company first
becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation, whichever event occurs first. 

6.    Miscellaneous. 

6.1    Successors and Assigns. The rights under this Agreement may be assigned (but only with
all related obligations) by a Holder to a transferee of Registrable Securities that is either: (a) an Affiliate of a Holder, (b) a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of
such Holder’s Immediate Family Members, or (c) after such transfer, a Holder of at least 500,000 shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other
recapitalizations); provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to
which such rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Subsection
2.11. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement is intended to confer upon any party other than the parties
hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 

6.2    Governing Law. This Agreement shall be governed by the internal law of the State of Delaware
without regard to conflict of law principles that would result in the application of any law other than the law of the State of Delaware; provided, however, that provisions specific to UC’s confidentiality and CPRA obligations set
forth in Section 3.5 and sovereign immunity and right to decline to be sued in federal court as set forth in Subsection 6.10 shall be construed in accordance with the laws of the State of California notwithstanding any applicable laws or
conflicts of laws principles. 
 6.3    Counterparts. This Agreement may be executed in two or
more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying
with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

  
 23 

 6.4    Titles and Subtitles. The titles and
subtitles used in this Agreement are for convenience only and are not to be considered in construing or interpreting this Agreement. 

6.5    Notices. 

(a)    All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be
deemed effectively given upon the earlier of actual receipt or: (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail or facsimile during the recipient’s normal business hours, and if not sent
during normal business hours, then on the recipient’s next business day; (iii) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one business day after the business
day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt. All communications shall be sent to the respective parties at
their addresses as set forth on Schedule A hereto, or to the principal office of the Company and to the attention of the Chief Executive Officer, in the case of the Company, or to such email address, facsimile number, or
address as subsequently modified by written notice given in accordance with this Subsection 6.5. 

(b)    Consent to Electronic Notice. Each Investor consents to the delivery of any stockholder notice pursuant to
the Delaware General Corporation Law (the “DGCL”), as amended or superseded from time to time, by electronic transmission pursuant to Section 232 of the DGCL (or any successor thereto) at the electronic mail address or the
facsimile number set forth below such Investor’s name on the Schedules hereto, as updated from time to time by notice to the Company, or as on the books of the Company. To the extent that any notice given by means of electronic transmission is
returned or undeliverable for any reason, the foregoing consent shall be deemed to have been revoked until a new or corrected electronic mail address has been provided, and such attempted Electronic Notice shall be ineffective and deemed to not have
been given. Each Investor agrees to promptly notify the Company of any change in such stockholder’s electronic mail address, and that failure to do so shall not affect the foregoing. 

6.6    Amendments and Waivers. Any term of this Agreement may be amended, modified or terminated and
the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of at least 51% of the Registrable
Securities then outstanding (but excluding for the specific purpose of this voting threshold shares of Common Stock issued or issuable solely as a result of the provisions of Article Fourth Section B(4.11) of the Certificate of Incorporation);
provided that the Company may in its sole discretion waive compliance with Subsection 2.12(c) (and the Company’s failure to object promptly in writing after notification of a proposed assignment allegedly in violation of
Subsection 2.12(c) shall be deemed to be a waiver); and provided further that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party.
Notwithstanding the foregoing: (a) this 

  
 24 

 
Agreement may not be amended, modified or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such
amendment, modification, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of Section 4 with respect to a particular transaction shall be deemed to apply to
all Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities in such transaction, so long as each Major Investor is
provided with an opportunity to purchase up to its portion of New Securities being offered in accordance with Subsection 4.1); (b) Subsections 3.1 and 3.2, Section 4, and any other section of this
Agreement applicable to the Major Investors (including this clause (b) of this Subsection 6.6) may not be amended, modified, terminated or waived without the written consent of the holders of at least 51% of the Registrable Securities
then outstanding and held by the Major Investors (but excluding for the specific purpose of this voting threshold shares of Common Stock issued or issuable solely as a result of the provisions of Article Fourth Section B(4.11) of the Certificate of
Incorporation); (c) so long as the UC holds any Registrable Securities, the provisions of Subsection 3.5, Subsection 6.2, this Subsection 6.6(c), and Subsection 6.10 may not be amended, terminated or waived in any manner
adverse to the UC without the consent of the UC and (d) Subsection 3.3 and this Subsection 6.6(d) may not be amended, modified, terminated or waived without the written consent of Gilead. Notwithstanding the foregoing, Schedule
A hereto may be amended by the Company from time to time to add transferees of any Registrable Securities in compliance with the terms of this Agreement without the consent of the other parties. The Company shall give prompt notice of any
amendment, modification or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, modification, termination, or waiver. Any amendment, modification, termination, or waiver effected in accordance
with this Subsection 6.6 shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances,
shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision. 

6.7    Severability. In case any one or more of the provisions contained in this Agreement is for
any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed
and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law. 

6.8    Aggregation of Stock. All shares of Registrable Securities held or acquired by Affiliates
shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate. 

6.9    Entire Agreement. This Agreement (including any Schedules and Exhibits hereto) constitutes
the full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. 

  
 25 

 6.10    Dispute Resolution. Subject to the last
sentence hereof, the parties: (a) hereby irrevocably and unconditionally submit to the jurisdiction of the Court of Chancery of the State of Delaware for the purpose of any suit, action or other proceeding arising out of or based upon this
Agreement, provided, that if jurisdiction is not then available in the Court of Chancery of the State of Delaware, then any such legal action or proceeding may be brought in any federal court located in the State of Delaware or any other
Delaware state court, (b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the above-named courts, and (c) hereby waive, and agree not to assert, by way of motion, as a
defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or
proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court. Notwithstanding the foregoing, the UC will not
be subject to the jurisdiction of a federal court and maintains its 11th Amendment right to decline to be sued in a federal court. 

WAIVER OF JURY TRIAL: EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT,
THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND
THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY
EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND
VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. 
 6.11    Delays
or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such non-breaching or non-defaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default
thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any
party, shall be cumulative and not alternative. 

  
 26 

 [Remainder of Page Intentionally Left Blank] 

  
 27 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	ALLOGENE THERAPEUTICS, INC.
		
	By:	 	 /s/ Joshua A. Kazam

	Name:	 	Joshua A. Kazam
	Title:	 	President

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	THE RISE FUND CARTHAGE, L.P.
	
	 By: The Rise Fund GenPar, L.P.

its General Partner

	 By: The Rise Fund GenPar Advisors, LLC

its General Partner

		
	By:	 	 /s/ Michael LaGatta

	Name:	 	Michael LaGatta
	Title:	 	Vice President
	
	TPG CARTHAGE HOLDINGS, L.P.
	
	 By: TPG GenPar VII, L.P.
 its
General Partner

	 By: TPG GenPar VII Advisors, LLC

its General Partner

		
	By:	 	 /s/ Adam Fliss

	Name:	 	Adam Fliss
	Title:	 	Vice President

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	VIDA VENTURES, LLC
	
	By: VV Manager, LLC, its Managing Member
		
	By:	 	 /s/ Fred Cohen

	Name:	 	Fred Cohen
	Title:	 	Senior Managing Director

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	VVAG SPECIAL FUND LLC
	
	By: VVAG LLC, its manager
		
	By:	 	 /s/ Fred Cohen

	Name:	 	Fred Cohen
	Title:	 	Senior Managing Member

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	PFIZER, INC.
		
	By:	 	 /s/ G. Mikael Dolsten

	Name:	 	G. Mikael Dolsten
	Title:	 	President, Worldwide Research & Development

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	GILEAD SCIENCES, INC.
		
	By:	 	 /s/ John F. Milligan, Ph.D.

	Name:	 	John F. Milligan, Ph.D.
	Title:	 	President and Chief Executive Officer

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
		
	By:	 	 /s/ Jagdeep Singh Bachher

	Name:	 	Jagdeep Singh Bachher
	Title:	 	Chief Investment Officer
	 	 	Regents of the University of California

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

	
	INVESTOR:
	
	 /s/ Veer Bhavnagri

	VEER BHAVNAGRI

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

	
	INVESTOR:
	
	 /s/ Joshua A. Kazam

	JOSHUA A. KAZAM

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

	
	INVESTOR:
	
	 /s/ David M. Tanen

	DAVID M. TANEN

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	SEAVIEW TRUST
		
	By:	 	 /s/ Joshua A. Kazam

	Name:	 	Joshua A. Kazam
	Title:	 	Trustee

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	BELLDEGRUN FAMILY TRUST
		
	By:	 	 /s/ Arie S. Belldegrun, M.D., FACS

	Name:	 	Arie S. Belldegrun, M.D., FACS
	Title:	 	Trustee

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	CHANG 2006 FAMILY TRUST
		
	By:	 	 /s/ David D. Chang

	Name:	 	David D. Chang
	Title:	 	Trustee

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

	
	INVESTOR:
	
	 /s/ Franz Humer

	FRANZ HUMER

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

	
	INVESTOR:
	
	 /s/ Own Witte

	OWEN WITTE

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

	
	INVESTOR:
	
	 /s/ Christine Cassiano

	CHRISTINE CASSIANO

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	KB/V LLC
	 By: Kingsbrook Opportunities GP LLC,

its Manager

		
	By:	 	 /s/ Scott M. Wallace

	Name:	 	Scott M. Wallace
	Title:	 	Managing Member

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

	
	INVESTOR:
	
	 /s/ James Economou

	JAMES ECONOMOU

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

	
	INVESTOR:
	
	 /s/ Allan Pantuck

	ALLAN PANTUCK

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

	
	INVESTOR:
	
	 /s/ Stuart Holder

	STUART HOLDEN

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

	
	INVESTOR:
	
	 /s/ Roy Doumani

	ROY DOUMANI

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

			
	INVESTOR:
	
	KIERNAN FAMILY TRUST
		
	By:	 	 /s/ Vera Kiernan

	Name:	 	Vera Kiernan
	Title:	 	Trustee

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

	
	INVESTOR:
	
	 /s/ Linda Barnes

	LINDA BARNES

  

SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT

 AMENDMENT TO INVESTORS’ RIGHTS AGREEMENT 

THIS AMENDMENT TO INVESTORS’ RIGHTS AGREEMENT (this “Amendment”) is made as of September 5, 2018, by and among
Allogene Therapeutics, Inc., a Delaware corporation (the “Company”), and the other individuals and entities listed on the signature pages hereto (the “Investors”), and amends that certain Investors’ Rights
Agreement, dated April 6, 2018, by and among the Company and the investors listed on Schedule A thereto (the “Agreement”). 

RECITALS 
 A. The Company
and the Investors have agreed to enter into this Amendment to modify the terms of the Agreement in connection with the sale and issuance of convertible promissory notes of the Company (the “Notes”) pursuant to that certain
Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 
 B. The
Agreement provides that any term of the Agreement may be amended only with the written consent of the Company and the holders of at least 51% of the Registrable Securities then outstanding (but excluding for the specific purpose of this voting
threshold shares of Common Stock issued or issuable solely as a result of the provisions of Article Fourth Section B(4.11) of the Certificate of Incorporation) (with each capitalized term having the meaning set forth in the Agreement). 

AGREEMENT 
 The parties
hereby agree as follows: 
 1. Section 1.23 of the Agreement is hereby amended and restated to read in full as follows: 

““Registrable Securities” means: (i) the Common Stock issuable or issued upon conversion of the Preferred Stock;
(ii) any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company, acquired by the Investors after the date hereof; (iii) any Common Stock issued upon conversion of the
Notes in connection with an Initial Public Offering (as defined in the Notes); and (iv) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other
distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses (i), (ii) and (iii) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the
applicable rights under this Agreement are not assigned pursuant to Subsection 6.1, and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Subsection 2.13
of this Agreement. For purposes of this Section 1.23, “Notes” shall mean the Company’s convertible promissory notes issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the
Company and the purchasers listed on Exhibit A thereto.” 
 2. Section 2.8(c) of the Agreement is hereby amended and restated to
read in full as follows: 
 “Promptly after receipt by an indemnified party under this Subsection 2.8 of notice of the
commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this
Subsection 2.8, give the indemnifying 

 
party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly with
any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties
that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if such indemnified party reasonably determines that representation by the
counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the
indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Subsection 2.8, to the extent that such failure materially
prejudices the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Subsection
2.8.” 
 3. Section 2.11 of the Agreement is hereby amended and restated to read in full as follows: 

““Market Stand-off” Agreement. Each Holder hereby
agrees, if requested by the managing underwriter, that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the registration by the
Company for its own behalf of shares of its Common Stock or any other equity securities under the Securities Act on a registration statement on Form S-1, and ending on the date specified by the Company and the managing
underwriter (such period not to exceed 180 days) (the “Lock-up Period”): (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or
contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for
Common Stock held immediately before the effective date of the registration statement for such offering, or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic
consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this
Subsection 2.11 shall: (A) apply only to the IPO; (B) not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, or the transfer of any shares to any trust for the direct or indirect benefit
of the Holder or the immediate family of the Holder, provided that the trustee of the trust agrees to be bound in writing by the restrictions set forth herein, and provided further that any such transfer shall not involve a
disposition for value; provided, however, that the foregoing restrictions shall not apply, in the case of a Holder that is an entity, to the transfer of any shares to an Affiliate of such Holder or any of the Holder’s
stockholders, members, partners or other equity holders, provided that such Affiliate, stockholder, member, partner or other equity holder agrees to be bound in writing by the restrictions set forth herein and no public disclosure or filing under
the Exchange Act by any party to the transfer (the Holder, Affiliate, stockholder, member, partner or other equity holder) shall be required, or made voluntarily, during the Lock-up Period; (C) be
applicable to the Holders only if all officers, directors, and stockholders individually owning more than 1% of the Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all

 
outstanding Preferred Stock) are subject to the same restrictions; and (D) not apply to the transfer of any shares acquired (x) from the underwriters in the IPO or (y) in open
market transactions on or after the IPO. In addition, if any officer, director or stockholder of the Company is granted an early release from the restrictions described this Subsection 2.11 during the
Lock-up Period with respect to more than 1% in the aggregate of the Company’s total outstanding common stock (whether in one or multiple releases), then each Major Investor shall also be granted an early
release from its obligations hereunder on a pro rata basis with all other record or beneficial holders of similarly restricted securities of the Company based on the maximum percentage of shares held by any such record or beneficial holder
being released from such holder’s lock-up agreement; provided, however, that in the case of an early release from the restrictions described herein during the
Lock-up Period in connection with an underwritten public offering, whether or not such offering or sale is wholly or partially a secondary offering of common stock (an “Underwritten Sale”),
such early release shall only apply with respect to the Major Investor’s participation in such Underwritten Sale so long as the Major Investor is given the ability to participate in such Underwritten Sale on a proportionate basis with the
holder being released. The underwriters in connection with such registration are intended third-party beneficiaries of this Subsection 2.11 and shall have the right, power and authority to
enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this
Subsection 2.11 or that are necessary to give further effect thereto. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Company
stockholders that are subject to such agreements, based on the number of shares subject to such agreements.” 
 4. Section 2.12
of the Agreement is hereby amended and restated to read in full as follows: 
 “Restrictions on Transfer. 

(a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not
recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the
provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the
provisions and upon the conditions specified in this Agreement. Notwithstanding the foregoing, the Company shall not require any transferee of shares pursuant to an effective registration statement or, following the IPO, pursuant to SEC Rule 144, in
each case, to be bound by the terms of this Agreement. 
 (b) Each certificate, instrument, or book entry representing (i) the
Preferred Stock, (ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or
similar event, shall (unless otherwise permitted by the provisions of Subsection 2.12(c)) be notated with a legend substantially in the following form: 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES
MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

 THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN
AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 
 The Holders consent to
the Company making a notation in its records and giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Subsection 2.12. 

The foregoing legend shall be removed from the certificates representing any Restricted Securities, at the request of the holder thereof, at
such time as (a) a period of at least one year, as determined in accordance with paragraph (d) of SEC Rule 144, has elapsed since the later of the date the Restricted Securities were acquired from the Company or an affiliate of the
Company, or (b) the Restricted Securities become eligible for resale pursuant to SEC Rule 144(b)(1)(i). 
 (c) The holder of such
Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is
in effect a registration statement under the Securities Act covering the proposed transaction or, following the IPO, the transfer is made pursuant to SEC Rule 144, the Holder thereof shall give notice to the Company of such Holder’s intention
to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such
Holder’s expense by either: (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction may be effected
without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation by
the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected
without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the
Company. The Company will not require such a legal opinion or “no action” letter: (x) in any transaction in compliance with SEC Rule 144; or (y) in any transaction in which such Holder distributes Restricted Securities to an
Affiliate of such Holder for no consideration; provided that, with respect to transfers under the foregoing clause (y), each transferee agrees in writing to be subject to the terms of this Subsection 2.12. Each certificate, instrument,
or book entry representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144 or pursuant to an effective registration statement, the appropriate restrictive legend
set forth in Subsection 2.12(b), except that such certificate instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to
establish compliance with any provisions of the Securities Act. 

 (d) The Company shall be obligated to reissue promptly unlegended certificates at the
request of any Holder thereof if the Company has completed its IPO or in connection with a sale of Registrable Securities by a Holder pursuant to SEC Rule 144 and the Company shall obtain an opinion of counsel reasonably acceptable to the Company to
the effect that the securities proposed to be disposed of may lawfully be so disposed of without registration, qualification and legend and provide such opinion to the transfer agent.” 

5. Schedule A of the Agreement is hereby amended to add the investors listed on Exhibit A attached hereto (each such investor, a
“New Investor”). Upon the execution of the counterpart signature page attached hereto as Exhibit B, each New Investor shall be deemed an “Investor,” a “Holder” and a party solely for purposes of
Section 2 (excluding Subsection 2.11) and Section 6 under the Agreement with respect to the Common Stock issued upon conversion of the Notes in connection with an Initial Public Offering (as defined in the Notes). 

6. All other provisions of the Agreement shall remain in full force and effect. 

7. This Amendment may be executed in any number of counterparts, each of which shall be enforceable against the parties actually executing
such counterparts, and all of which together shall constitute one instrument. 
 8. This Amendment shall be construed in accordance with the
laws of the State of Delaware, excluding conflicts of laws principles. 
 9. This Amendment and the Agreement and all exhibits hereto or
thereto are intended to be the sole agreement of the parties as they relate to the subject matter hereof and thereof and do hereby supersede all other agreements of the parties relating to the subject matter hereof or thereof. 

[Signature pages follow] 

 IN WITNESS WHEREOF, the parties have executed this Amendment to be effective as of
the date first above written. 
  

			
	COMPANY:
	
	ALLOGENE THERAPEUTICS, INC.
		
	By:	 	/s/ David Chang, M.D., Ph.D.

 
			
	Name:	 	David Chang, M.D., Ph.D.

 
			
	Title:	 	President and Chief Executive Officer

 [SIGNATURE PAGE TO AMENDMENT
TO INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amendment to be effective as of
the date first above written. 
  

			
	INVESTOR:
	
	THE RISE FUND CARTHAGE, L.P.
	
	By: The Rise Fund GenPar, L.P.

 
			
	its General Partner
	By: The Rise Fund GenPar Advisors, LLC
	its General Partner
		
	By:	 	/s/ Michael LaGatta

 
			
	Name:	 	Michael LaGatta

 
			
	Title:	 	Vice President
	
	TPG CARTHAGE HOLDINGS, L.P.
	
	By: TPG GenPar VII, L.P.
	its General Partner
	By: TPG GenPar VII Advisors, LLC
	its General Partner

 
			
		
	By:	 	/s/ Adam Fliss

 
			
	Name:	 	Adam Fliss

 
			
	Title:	 	Vice President

 [SIGNATURE PAGE TO AMENDMENT
TO INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amendment to be effective as of
the date first above written. 
  

			
	INVESTOR:
	
	VVAG SPECIAL FUND LLC
	
	By: VVAG LLC, its manager
		
	By:	 	/s/ Fred Cohen
	Name: Fred Cohen
	Title: Senior Managing Director

  

			
	VIDA VENTURES, LLC
	
	By: VV Manager LLC, its manger
		
	By:	 	/s/ Fred Cohen
	Name: Fred Cohen
	Title: Senior Managing Director

 [SIGNATURE PAGE TO AMENDMENT
TO INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amendment to be effective as of
the date first above written. 
  

			
	INVESTOR:
	
	GILEAD SCIENCES, INC.
		
	By:	 	/s/ John F. Milligan, Ph.D.
	Name: John F. Milligan, Ph.D.
	Title: President and Chief Executive Officer

 [SIGNATURE PAGE TO AMENDMENT
TO INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amendment to be effective as of
the date first above written. 
  

			
	INVESTOR:
	
	PFIZER, INC.
		
	By:	 	/s/ Douglas E. Giordano
	Name: Douglas E. Giordano
	Title: SVP of Worldwide Business Development

 [SIGNATURE PAGE TO AMENDMENT
TO INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amendment to be effective as of
the date first above written. 
  

			
	INVESTOR:
	
	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
		
	By:	 	/s/ Jagdeep Singh Bachher
	Name: Jagdeep Singh Bachher
	Title: Chief Investment Officer
	         Regents of the University of California

 [SIGNATURE PAGE TO AMENDMENT
TO INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amendment to be effective as of
the date first above written. 
  

			
	INVESTOR:
	
	BELLDEGRUN FAMILY TRUST
		
	By:	 	/s/ Arie Belldegrun, M.D., FACS
	Name: Arie Belldegrun, M.D., FACS
	Title: Trustee

 [SIGNATURE PAGE TO AMENDMENT
TO INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amendment to be effective as of
the date first above written. 
  

			
	INVESTOR:
		
	By:	 	/s/ Joshua A. Kazam
	Name: JOSHUA A. KAZAM

 [SIGNATURE PAGE TO AMENDMENT
TO INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amendment to be effective as of
the date first above written. 
  

			
	INVESTOR:
		
	By:	 	/s/ David M. Tanen
	Name: DAVID M. TANEN

 [SIGNATURE PAGE TO AMENDMENT
TO INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amendment to be effective as of
the date first above written. 
  

			
	INVESTOR:
	
	SEAVIEW TRUST
		
	By:	 	/s/ Hanna Ackerman
	Name: Hanna Ackerman
	Title: Trustee

 [SIGNATURE PAGE TO AMENDMENT
TO INVESTORS’ RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the parties have executed this Amendment to be effective as of
the date first above written. 
  

			
	INVESTOR:
	
	CHANG 2006 FAMILY TRUST
		
	By:	 	/s/ David Chang, M.D., Ph.D.
	Name: David Chang, M.D., Ph.D.
	Title: Trustee

 [SIGNATURE PAGE TO AMENDMENT
TO INVESTORS’ RIGHTS AGREEMENT] 

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018 
  

					
	 INVESTORS:

	
	SMALLCAP World Fund, Inc.
		
	By:	 	Capital Research and Management Company, for and on behalf of SMALLCAP World Fund, Inc.
			
		 	By:	 	/s/ Mark E. Brubaker
		 	Name:  	 	Mark E. Brubaker
		 	Title:	 	Authorized Signatory
	
	American Funds Insurance Series – Global Small Capitalization Fund
		
	By:	 	Capital Research and Management Company, for and on behalf of American Funds Insurance Series – Global Small Capitalization Fund
			
		 	By:	 	/s/ Mark E. Brubaker
		 	Name:  	 	Mark E. Brubaker
		 	Title:	 	Authorized Signatory

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018 
  

			
	INVESTORS:
	
	T. Rowe Price New Horizons Fund, Inc.
	T. Rowe Price New Horizons Trust
	T. Rowe Price U.S. Equities Trust
	 MassMutual Select Funds—MassMutual Select

T. Rowe Price Small and Mid Cap Blend Fund

	Each account, severally not jointly
		
	By:	 	T. Rowe Price Associates, Inc., Investment Adviser or Subadviser, as applicable

 
					
			
		 	By:	 	/s/ J. David Wagner

 
					
		 	Name: 	 	J. David Wagner

 
					
		 	Title: 	 	Vice President

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018 
  

			
	INVESTORS:
	
	T. Rowe Price Health Sciences Fund, Inc.
	TD Mutual Funds – TD Health Sciences Fund
	VALIC Company I – Health Sciences Fund
	T. Rowe Price Health Sciences Portfolio
	Each account, severally not jointly
		
	By:	 	T. Rowe Price Associates, Inc., Investment Adviser or Subadviser, as applicable

 
					
			
		 	By:	 	/s/ John C. Hall
		 	Name:	 	John C. Hall
		 	Title:	 	Vice President

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018 
  

			
	INVESTOR:
	
	PERCEPTIVE LIFE SCIENCES MASTER FUND LTD.

 
			
		
	By:	 	/s/ Adam Stone 

 
			
	Name: Adam Stone

 
			
	Title: C.I.O.

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018 
  

			
	INVESTORS:
	
	FIDELITY MT. VERNON STREET TRUST: FIDELITY SERIES GROWTH COMPANY
FUND

 
			
		
	By:	 	/s/ Colm Hogan

 
			
	Name: Colm Hogan
	Title: Authorized Signatory

 
			
	
	FIDELITY MT. VERNON STREET TRUST: FIDELITY GROWTH COMPANY
FUND

 
			
		
	By:	 	/s/ Colm Hogan

 
			
	Name: Colm Hogan
	Title: Authorized Signatory

 
			
	
	FIDELITY GROWTH COMPANY COMMINGLED POOL

 
			
	By: Fidelity Management Trust Company, as Trustee

 
			
		
	By:	 	/s/ Colm Hogan

 
			
	Name: Colm Hogan

 
			
	Title: Authorized Signatory

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018 
  

			
	INVESTORS:
	
	BLACKROCK HEALTH SCIENCES MASTER UNIT TRUST
	By:	 	BlackRock Capital Management, Inc.
	Its:	 	Investment Advisor

  

			
	By:	 	/s/ Hongying Xie 
	Name: Hongying Xie
	Title: Managing Director

  

			
	BLACKROCK HEALTH SCIENCES TRUST
	By:	 	BlackRock Advisors, LLC
	Its:	 	Investment Advisor

  

			
	By:	 	/s/ Hongying Xie 
	Name: Hongying Xie
	Title: Managing Director

  

			
	BLACKROCK HEALTH SCIENCES OPPORTUNITIES PORTFOLIO, A SERIES OF
BLACKROCK FUNDS
	By:	 	BlackRock Advisors, LLC
	Its:	 	Investment Advisor

  

			
	By:	 	/s/ Hongying Xie 
	Name: Hongying Xie
	Title: Managing Director

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018 
  

			
	INVESTOR:
	
	VENBIO SELECT FUND LLC
		
	By:	 	/s/ Behzad Aghazadeh
	Name: Behzad Aghazadeh
	Title: Portfolio Manager

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018 
  

			
	INVESTOR:
	
	CITADEL MULTI-STRATEGY EQUITIES MASTER FUND LTD.
	By: Citadel Advisors LLC, its portfolio manager
		
	By:	 	/s/ Shellane Mulcahy
	Name: Shellane Mulcahy
	Title: Authorized Signatory

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018 
  

			
	INVESTOR:
	
	DEERFIELD SPECIAL SITUATIONS FUND, L.P.
	 By: Deerfield Mgmt, L.P.

       General Partner

	 By: J.E. Flynn Capital, LLC

       General Partner

		
	By:	 	/s/ David J. Clark
	Name: David J. Clark
	Title: Authorized Signatory

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018 
  

			
	INVESTOR:

 
			
	
	FRANKLIN STRATEGIC SERIES – FRANKLIN BIOTECHNOLOGY DISCOVERY
FUND

 
			
	
	By: Franklin Advisers, Inc., as Investment Manager

 
			
		
	By:	 	/s/ Evan McCulloch

 
			
	Name: Evan McCulloch

 
			
	Title: Vice President

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018 
  

			
	INVESTOR:
	
	JENNISON GLOBAL HEALTHCARE MASTER FUND, LTD.
	
	By: Jennison Associates LLC, as Investment Manager of Jennison Global Healthcare Master Fund, Ltd.
		
	By:	 	/s/ David Chan

 
			
	Name: David Chan
	Title: Managing Director of Jennison Associates LLC and Portfolio Manager of the Fund

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018 
  

							
		 	INVESTOR (if an entity):
		
	Name of Investor:	 	AL Co-Investment LLC
			
		 	By:  	 	/s/ Owen Littman
		 		 	Name:	 	Owen Littman
		 		 	Title:	 	Authorized Signatory
		
		 	INVESTOR (if an individual):
		
	Name of Investor:	 	 
		
	Signature: 	 	 

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018 
  

							
		 	INVESTOR (if an entity):
		
	Name of Investor:	 	Procurator Holdings, LLC
			
		 	By:  	 	/s/ Victor Chiang
		 		 	Name:	 	Victor Chiang
		 		 	Title:	 	Managing Member
		
		 	INVESTOR (if an individual):
		
	Name of Investor:	 	 
		
	Signature: 	 	 

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018 
  

							
		 	INVESTOR (if an entity):
		
	Name of Investor:	 	South Bay Capital Partners, LLC
			
		 	By:  	 	/s/ Maurice Marciano
		 		 	Name:	 	Maurice Marciano
		 		 	Title:	 	Manager
		
		 	INVESTOR (if an individual):
		
	Name of Investor:	 	 
		
	Signature: 	 	 

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018 
  

							
		 	INVESTOR (if an entity):
		
	Name of Investor:	 	 
			
		 	By:  	 	 
		 		 	Name:	 	 
		 		 	Title:	 	 
		
		 	INVESTOR (if an individual):
		
	Name of Investor:	 	Richard S. Ressler
		
	Signature: 	 	/s/ Richard S. Ressler

  

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018 
  

							
		 	INVESTOR (if an entity):
		
	Name of Investor:	 	Stella Maris Holding Corp.
			
		 	By:  	 	/s/ Daniel Stutz /s/ Rudy Buhler
		 		 	Name:	 	Daniel Stutz Rudy Buhler
		 		 	Title:	 	Corporate Directors
		
		 	INVESTOR (if an individual):
		
	Name of Investor:	 	 
		
	Signature: 	 	 

  

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018     

 

							
		 	INVESTOR (if an entity):
		
	Name of Investor:	 	 
			
		 	By:  	 	 
		 		 	Name:	 	 
		 		 	Title:	 	 
		
		 	INVESTOR (if an individual):
		
	Name of Investor:	 	Mr. Ran Rahav
		
	Signature: 	 	/s/ Mr. Ran Rahav

  

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018     

 

							
		 	INVESTOR (if an entity):
		
	Name of Investor:	 	Quartet, L.P.
			
		 	By:  	 	/s/ Russell Goldsmith
		 		 	Name:	 	Russell Goldsmith
		 		 	Title:	 	General Partner
		
		 	INVESTOR (if an individual):
		
	Name of Investor:	 	 
		
	Signature: 	 	 

  

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018     

 

							
		 	INVESTOR (if an entity):
		
	Name of Investor:	 	 
			
		 	By:  	 	 
		 		 	Name:	 	 
		 		 	Title:	 	 
		
		 	INVESTOR (if an individual):
		
	Name of Investor:	 	Avi Arad
		
	Signature: 	 	/s/ Avi Arad

  

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018     

 

							
		 	INVESTOR (if an entity):
		
	Name of Investor:	 	 
			
		 	By:  	 	 
		 		 	Name:	 	 
		 		 	Title:	 	 
		
		 	INVESTOR (if an individual):
		
	Name of Investor:	 	Tiomkin Avi
		
	Signature: 	 	/s/ Tiomkin Avi

  

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018     

 

							
		 	INVESTOR (if an entity):
		
	Name of Investor:	 	 
			
		 	By:  	 	 
		 		 	Name:	 	 
		 		 	Title:	 	 
		
		 	INVESTOR (if an individual):
		
	Name of Investor:	 	Harry Sloan
		
	Signature: 	 	/s/ Harry Sloan

  

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018     

 

							
		 	INVESTOR (if an entity):
		
	Name of Investor:	 	SUMMIT COMMERCIAL INTERNATIONAL SA
		 	 By:
	 	ELPIDIA FINANCE INC. AS DIRECTOR
			
		 	By:  	 	/s/ Teresa de Herrero
		 		 	Name: Teresa de Herrero
		 		 	Title: Director
		
		 	INVESTOR (if an individual):
		
	Name of Investor: 	 	 
		
	Signature: 	 	 

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018     

 

							
		 	INVESTOR (if an entity):
		
	Name of Investor:	 	 
			
		 	By:  	 	 
		 		 	Name:	 	 
		 		 	Title:	 	 
		
		 	INVESTOR (if an individual):
		
	Name of Investor:	 	Anton Linderum
		
	Signature: 	 	/s/ Anton Linderum

  

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018     

 

							
		 	INVESTOR (if an entity):
		
	Name of Investor:	 	Dominick Fernando Mills Jr. and Christine Cassiano Family Trust
			
		 	By:  	 	/s/ Dominick F. Mills
		 		 	Name:	 	Dominick F. Mills
		 		 	Title:	 	Trustee
		
		 	INVESTOR (if an individual):
		
	Name of Investor: 	 	 
		
	Signature: 	 	 

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018     

 

							
		 	INVESTOR (if an entity):
		
	Name of Investor:	 	 
			
		 	By:  	 	 
		 		 	Name:	 	 
		 		 	Title:	 	 
		
		 	INVESTOR (if an individual):
		
	Name of Investor:	 	Cynthia M. Butitta
		
	Signature: 	 	/s/ Cynthia M. Butitta

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018     

 

							
		 	INVESTOR (if an entity):
		
	Name of Investor:	 	 
			
		 	By: 	 	 
		 		 	Name:	 	 
		 		 	Title:	 	 
		
		 	INVESTOR (if an individual):
		
	Name of Investor:	 	Frederic D. Rosen
		
	Signature: 	 	/s/ Frederic D. Rosen

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018     

 

							
		 	INVESTOR (if an entity):
		
	Name of Investor:	 	Sonostar Ventures LLC
			
		 	By: 	 	/s/ Gregory Kiernan
		 		 	Name:	 	Gregory Kiernan
		 		 	Title:	 	CEO
		
		 	INVESTOR (if an individual):
		
	Name of Investor:	 	 
		
	Signature: 	 	 

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018     

 

							
		 	INVESTOR (if an entity):
		
	Name of Investor:	 	Mann Living Trust
			
		 	By: 	 	/s/ Robert S. Mann
		 		 	Name:	 	Robert S. Mann
		 		 	Title:	 	Trustee
		
		 	INVESTOR (if an individual):
		
	Name of Investor:	 	 
		
	Signature:	 	 

  

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018     

 

							
		 	INVESTOR (if an entity):
		
	Name of Investor:	 	Sherry Lansing Trust dtd 4/23/88
			
		 	By: 	 	/s/ Sherry Lansing
		 		 	Name:	 	Sherry Lansing
		 		 	Title:	 	Trustee
		
		 	INVESTOR (if an individual):
		
	Name of Investor:	 	 
		
	Signature: 	 	 

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018     

 

							
		 	INVESTOR (if an entity):
		
	Name of Investor:	 	 
			
		 	By: 	 	 
		 		 	Name:	 	 
		 		 	Title:	 	 
		
		 	INVESTOR (if an individual):
		
	Name of Investor:	 	Hanna Ackerman
		
	Signature: 	 	/s/ Hanna Ackerman

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018 
  

							
		 	INVESTOR (if an entity):
		
	Name of Investor:	 	 
			
		 	By: 	 	 
		 		 	Name:	 	 
		 		 	Title:	 	 
		
		 	INVESTOR (if an individual):
		
	Name of Investor:	 	Linda Barnes
		
	Signature: 	 	/s/ Linda Barnes

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018 
  

							
		 	INVESTOR (if an entity):
		
	Name of Investor:	 	 
			
		 	By: 	 	 
		 		 	Name:	 	 
		 		 	Title:	 	 
		
		 	INVESTOR (if an individual):
		
	Name of Investor:	 	Joshua Lennon Bradley
		
	Signature: 	 	/s/ Joshua Lennon Bradley

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018     

 

							
		 	INVESTOR (if an entity):
		
	Name of Investor:	 	 
			
		 	By: 	 	 
		 		 	Name:	 	 
		 		 	Title:	 	 
		
		 	INVESTOR (if an individual):
		
	Name of Investor:	 	Christopher M. Wilfong
		
	Signature:	 	/s/ Christopher M. Wilfong

  

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018     

 

							
		 	INVESTOR (if an entity):
		
	Name of Investor:	 	 
			
		 	By: 	 	 
		 		 	Name:	 	 
		 		 	Title:	 	 
		
		 	INVESTOR (if an individual):
		
	Name of Investor:	 	Sean Algeo
		
	Signature:	 	/s/ Sean Algeo

  

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018     

 

							
		 	INVESTOR (if an entity):
		
	Name of Investor:	 	 
			
		 	By: 	 	 
		 		 	Name:	 	 
		 		 	Title:	 	 
		
		 	INVESTOR (if an individual):
		
	Name of Investor:	 	Laura Whelan
		
	Signature:	 	/s/ Laura Whelan

  

 COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September 5, 2018     

 

							
		 	INVESTOR (if an entity):
		
	Name of Investor:	 	Messemer Family Trust dated February 18, 2003
			
		 	By: 	 	/s/ Deborah McDonald Messemer
		 		 	Name:	 	Deborah McDonald Messemer
		 		 	Title:	 	Trustee
		
		 	INVESTOR (if an individual):
		
	Name of Investor: 	 	 
		
	Signature:	 	 

  

 EXHIBIT A 

Investors 

 EXHIBIT B 

COUNTERPART SIGNATURE PAGE TO 

ALLOGENE THERAPEUTICS, INC. 

INVESTORS’ RIGHTS AGREEMENT 

The undersigned is a holder of a convertible promissory note (the “Note”) of Allogene Therapeutics, Inc. (the
“Company”) issued pursuant to that certain Note Purchase Agreement, dated September 5, 2018, by and among the Company and the purchasers listed on Exhibit A thereto. 

The undersigned hereby agrees to be bound by the terms and conditions contained in the Investors’ Rights Agreement, dated April 6,
2018, as amended from time to time, by and among the Company and the investors listed on Schedule A thereto, a copy of which is attached hereto as EXHIBIT A (the
“Investors’ Rights Agreement”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Investors’ Rights Agreement. 

Upon the execution this counterpart signature page, the undersigned shall be deemed an “Investor,” a “Holder” and a party
solely for purposes of Section 2 (but excluding Subsection 2.11) under the Investors’ Rights Agreement with respect to the any Common Stock issued upon conversion of the Note in connection with an Initial Public Offering (as defined in the
Note). 
 Dated: September ___, 2018     
  

							
		 	INVESTOR (if an entity):
		
	Name of Investor:	 	 
			
		 	By: 	 	 
		 		 	Name:	 	 
		 		 	Title:	 	 
		
		 	INVESTOR (if an individual):
		
	Name of Investor:	 	 
		
	Signature:	 	 

  

 EXHIBIT A 

INVESTORS’ RIGHTS AGREEMENTEX-10.2

 Exhibit 10.2 

ALLOGENE THERAPEUTICS, INC. 

AMENDED AND RESTATED 

2018 EQUITY INCENTIVE PLAN 

1.    GENERAL. 

(a)    Purpose. This Allogene Therapeutics, Inc. Amended and Restated 2018 Equity Incentive Plan (the
“Plan”) is intended to help the Company secure and retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of Allogene Therapeutics, Inc. (the
“Company”) and any Affiliate, and provide a means by which eligible recipients may benefit from the Company’s future performance through the grant of Awards covering Common Stock. Capitalized terms not defined in the
text of the Plan are defined in Section 15. 
 (b)    Eligible Award Recipients. Employees, Directors
and Consultants are eligible to receive Awards. 
 (c)    Available Awards. The Plan provides for the
grant of the following Awards: (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Restricted Stock Awards, (iv) Restricted Stock Unit Awards, and (vi) Other Stock-Based Awards. 

2.    ADMINISTRATION. 

(a)    Administration of the Plan. The Plan will be administered by the Company’s Board of Directors
(the “Board”), or at the discretion of the Board, by a committee of one or more Directors to whom authority has been delegated by the Board in accordance with applicable law (a “Committee”). The Board
may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated. 

(b)    Powers of the Board. The Board will have the power, subject to, and within the limitations of, the
express provisions of the Plan: 
 (i)    To determine: (A) who will be granted Awards; (B) when and
how each Award will be granted; (C) what type of Award will be granted; (D) the provisions of each Award (which need not be identical), including when a person will be permitted to exercise or otherwise receive cash or Common Stock under
the Award; (E) the number of shares of Common Stock subject to, or the cash value of, an Award; and (F) the Fair Market Value applicable to an Award. 

(ii)    To construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke rules
and regulations for administration of the Plan and Awards. The Board, in the exercise of these powers, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement, in a manner and to the extent it will deem necessary or
expedient to make the Plan or Award fully effective. 

  
 1. 

 (iii)    To settle all controversies regarding the Plan and
Awards granted under it. 
 (iv)    To accelerate, in whole or in part, the time at which an Award may be
exercised or vest (or the time at which cash or shares of Common Stock may be issued in settlement thereof). 

(v)    To suspend or terminate the Plan at any time. Suspension or termination of the Plan will not impair rights
and obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant. 

(vi)    To amend the Plan in any respect the Board deems necessary or advisable, subject to the limitations, if
any, of applicable law, and to submit any amendment to the Plan for stockholder approval to the extent deemed necessary or desirable. 

(vii)    To amend the terms of any one or more Awards, including to modify the vesting terms, subject to consent of
the Participant if such amendment would materially impair such Participant’s rights. A Participant’s rights will not be deemed to be materially impaired by any amendment solely because the change impairs the qualified status of an Option
as an Incentive Stock Option under Section 422 of the Code. In addition, the Board may unilaterally amend an Award (regardless of whether it impairs a Participant’s rights) in order to clarify the manner of exemption from, or to bring the
Award into compliance with, Section 409A of the Code, or to comply with other applicable laws. 

(viii)    To adopt such procedures and sub-plans as are necessary or
appropriate to facilitate participation in the Plan by Employees, Directors or Consultants who are foreign nationals or employed outside the United States. 

(ix)    To effect, with the consent of any materially adversely affected Participant, the reduction of the
exercise, purchase or strike price of any outstanding Award, or any other action that is treated as a repricing under generally accepted accounting principles. 

(x)    Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to
promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards. 

(c)    Limited Delegation of Grantmaking Authority to an Officer. The Board may
delegate to one or more Officers the authority to designate Employees who are not Officers to be recipients of Awards and, to the extent permitted by applicable law, the terms of such Awards, and determine the number of shares of Common Stock to be
subject to such Awards granted to such Employees; provided, however, that the Board resolutions regarding such delegation will specify the total number of shares of Common Stock that may be subject to the Awards granted by such Officer
and that such Officer may not grant an Award to himself or herself. Any such Awards will be granted on the form of Award Agreement most recently approved for use by the Committee or the Board, unless otherwise provided in the resolutions approving
the delegation authority. The Board may not delegate authority to an Officer who is acting solely in the capacity of an Officer (and not also as a Director) to determine the Fair Market Value pursuant to Section 15(q) below. 

(d)    Stock Plan Administrator. The Board may appoint one or more Officers to act as the Board’s
designee to administer the day-to-day operations of the Plan, and to make ministerial decisions regarding the Plan and Awards as expressly provided for in the Plan or
any Award Agreement (the “Stock Plan Administrator”). Without limiting the foregoing, the Stock Plan Administrator will have the power 

  
 2. 

 
to: (i) determine whether Continuous Service will be considered interrupted, or whether vesting of Awards will be tolled, during an approved leave of absence or in connection with transfers
between the Company, an Affiliate, or their successors; (ii) approve specific methods of payment for the exercise price of an Option at the time of exercise; (iii) approve amendments to forms of Award Agreements previously adopted by the
Board to facilitate participation in the Plan by foreign nationals or comply with applicable law; (iv) impose a black-out period during which time Option exercises are prohibited (up to a maximum of
thirty days) in connection with any pending Capitalization Adjustment, third party valuation of the Shares, or Corporate Transaction; and (v) approve extensions of the post-termination exercise period of an Option in connection with the
termination of a Participant’s Continuous Service (but not beyond the original term of the Option). 

(e)    Corporate Action Constituting Grant of Awards. The grant date of an Award will be the date on which
the Board adopts a resolution, or takes other appropriate action, expressly granting an Award to a Participant that specifies the key terms and conditions of the Award (e.g., exercise price, vesting schedule, and number of shares); provided,
that if a later effective grant date is set forth in such resolution, then such date as is set forth in such resolution will be the grant date. 

(f)    Effect of Board’s Decision. All determinations, interpretations and constructions made by the
Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons. 

3.    SHARES SUBJECT TO THE PLAN.

 (a)    Share Reserve. 

(i)    Subject to Section 9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common
Stock that may be issued pursuant to Awards from and after the Effective Date will not exceed 2,325,553 shares (the “Share Reserve”). 

(ii)    For clarity, the Share Reserve in this Section 3(a) is a limitation on the number of shares of Common
Stock that may be issued pursuant to the Plan. Accordingly, this Section 3(a) does not limit the granting of Awards except as provided in Section 7(a). 

(b)    Reversion of Shares to the Share Reserve. If an Award or any portion thereof (i) expires or
otherwise terminates without all of the shares covered by such Award having been issued or (ii) is settled in cash (i.e., the Participant receives cash rather than stock), such expiration, termination or settlement will not reduce (or
otherwise offset) the number of shares of Common Stock that may be available for issuance under the Plan. If any shares of Common Stock issued pursuant to an Award are forfeited back to or repurchased by the Company because of the failure to meet a
contingency or condition required to vest such shares in the Participant, then the shares that are forfeited or repurchased will revert to and again become available for issuance under the Plan. Any shares reacquired by the Company in satisfaction
of tax withholding obligations on an Award or as consideration for the exercise or purchase price of an Award will again become available for issuance under the Plan. 

(c)    Incentive Stock Option Limit. Subject to the Share Reserve and Section 9(a) relating to
Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options will be a number of shares of Common Stock equal to three (3) multiplied by the Share
Reserve, as may be increased from time to time. 

  
 3. 

 (d)    Source of Shares; Use of Proceeds. The stock
issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company. Proceeds from the sale of Shares pursuant to Awards will constitute general funds of the Company. 

4.    ELIGIBILITY. 

(a)    Eligibility for Specific Awards. Awards may be granted to Employees, Directors and Consultants, except
that Incentive Stock Options may only be granted only to employees of the Company or a “parent corporation” or “subsidiary corporation” thereof (as such terms are defined in Sections 424(e) and 424(f) of the Code). 

(b)    Consultants. A Consultant will not be eligible for the grant of an Award if, at the time of grant,
either the offer or sale of the Company’s securities to such Consultant is not exempt under Rule 701 of the Securities Act because of the nature of the services that the Consultant is providing to the Company, because the Consultant is not
a natural person, or because of any other provision of Rule 701, unless the Company determines that such grant need not comply with the requirements of Rule 701 and will satisfy another exemption under the Securities Act as well as comply
with the securities laws of all other relevant jurisdictions. 
 5.    PROVISIONS RELATING
TO OPTIONS. 
 An “Option” means any option to purchase shares of stock. Each
Option will be subject to the conditions set forth in this Section 5, and such other conditions not inconsistent with the Plan as may reflected in the applicable Award Agreement. 

(a)    Designation of ISO or NSO Status. All Options will be separately designated Incentive Stock Options
or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates will be issued for shares of Common Stock purchased on exercise of each type of Option. If an Option is not specifically
designated as an Incentive Stock Option, or if an Option is designated as an Incentive Stock Option but some portion or all of the Option fails to qualify as an Incentive Stock Option under the applicable rules, then the Option (or portion thereof)
will be a Nonstatutory Stock Option. 
 (b)    Term. Subject to the provisions of Section 5(f)
regarding Ten Percent Stockholders, no Option will be exercisable after the expiration of ten years from the date of its grant or such shorter period specified in the Award Agreement. 

(c)    Exercise Price. Subject to the provisions of Section 5(f) regarding Ten Percent Stockholders,
the exercise price of each Option will be not less than 100% of the Fair Market Value of the Common Stock subject to the Option on the date the Award is granted. Notwithstanding the foregoing, an Option may be granted with an exercise price lower
than 100% of the Fair Market Value of the Common Stock if such Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the
provisions of Section 409A of the Code and, if applicable, Section 424(a) of the Code. 

(d)    Option Exercise and Payment of Exercise Price. To exercise any outstanding Option, the Participant
must provide notice of exercise to the Stock Plan Administrator in compliance with the provisions of the Award Agreement evidencing such Option. The purchase price of Common Stock acquired pursuant to the exercise of an Option will be paid, to the
extent permitted by applicable law, by any combination of the methods of payment set forth below. The Board has the authority to grant Options 

  
 4. 

 
that do not permit all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to utilize a
particular method of payment. The permitted methods of payment are as follows: 
 (i)    by cash, check, bank
draft or money order payable to the Company; 
 (ii)    provided that at the time of exercise the Common Stock is
publicly traded and the Company has established procedures for cashless exercise, pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the stock subject to the Option, results
in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds; 

(iii)    by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock duly
endorsed for transfer to the Company, with a Fair Market Value on the date of delivery equal to the exercise price (or portion thereof) due for the number of shares being acquired; 

(iv)    provided that at the time of exercise the Company has established procedures for accepting such payment via
a “net exercise,” if an Option is a Nonstatutory Stock Option, by a “net exercise” arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of
shares with a Fair Market Value that does not exceed the aggregate exercise price; 
 (v)    according to a
deferred payment or similar arrangement with the Participant; provided, however, that interest will compound at least annually and will be charged at the minimum rate of interest necessary to avoid (A) the imputation of interest income to the
Company and compensation income to the Participant under any applicable provisions of the Code, and (B) the classification of the Option as a liability for financial accounting purposes; or 

(vi)    in any other form of legal consideration that may be acceptable to the Board. 

(e)    Incentive Stock Option $100,000 Limitations. To the extent that the aggregate Fair Market Value
(determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Participant during any calendar year (under all plans of the Company and any Affiliates) exceeds $100,000 (or
such other limit established in the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not
comply with such rules will be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Award Agreement(s). 

(f)    Incentive Stock Options granted to Ten Percent Stockholders. A Ten Percent Stockholder may only be
granted an Incentive Stock Option if the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant and the Option is not exercisable after the expiration of five (5) years from the date of grant. If a
purported grant of an Incentive Stock Option to a Ten Percent Stockholder does not meet these requirements, the grant will be a Nonstatutory Stock Option. 

(g)    Restrictions on Transfer. An Incentive Stock Option will not be transferable except by will or by the
laws of descent and distribution, and will be exercisable during the lifetime of the Participant only by the Participant. A Nonstatutory Stock Option may, in the sole discretion of the Board, be transferable upon written approval by the Board and in
a manner that is not prohibited by applicable tax and securities laws; provided that the Participant and the transferee enter into a transfer agreement in a form required by the Company. Except as explicitly provided in the Plan, an Option
may not be transferred for consideration. 

  
 5. 

 (h)    Exercise Restrictions; Early Exercise. The Board
may impose such restrictions on or conditions to the exercisability of Options and Stock Appreciation Rights as it, in its sole discretion, deems appropriate. The exercisability provisions of individual Options or Stock Appreciation Rights may vary.
Except as otherwise provided in the Award Agreement or an individual agreement with the Participant, vesting will cease upon termination of the Participant’s Continuous Service. An Option may include an “early exercise” provision
whereby the Participant may exercise the Option as to any part or all of the shares of Common Stock subject to the Option prior to the full vesting of the Option, and where any unvested shares of Common Stock so purchased may be subject to a
repurchase right in favor of the Company or to any other restriction the Board determines to be appropriate. 

(i)    Termination of Continuous Service. If a Participant’s Continuous Service terminates, the
Participant may exercise his or her Option (to the extent that the Participant was entitled to exercise the vested portion of such Award as of the date of termination of Continuous Service) but only within such period of time following the
termination of the Participant’s Continuous Service as set forth in the Award Agreement. Unless otherwise provided in the Award Agreement, the Option will be exercisable for a period of three (3) months following a termination of a
Participant’s Continuous Service by the Company without Cause or by the Participant for any reason; provided, however that such post-termination exercise period will instead be for the twelve (12) month period following a
termination due to Disability, and an eighteen (18) month period following a termination due to the Participant’s death. Additionally, if the Participant’s death occurs within the applicable post-termination of Continuous Service
period during which the Option was exercisable, the Option will be exercisable for an eighteen (18) month period following the Participant’s death. If, after termination of Continuous Service, the Participant does not exercise his or her
Option prior to the applicable deadline the Option will terminate. 
 (j)    Automatic Extension of
Termination Date. If the exercise of an Option following the termination of the Participant’s Continuous Service for any reason other than for Cause would be prohibited at any time solely because the issuance of shares of Common Stock would
violate the registration requirements under the Securities Act, then the Option will terminate on the earlier of (i) the expiration of a period equal to the applicable post-termination exercise period after the termination of the
Participant’s Continuous Service during which the exercise of the Option would not be in violation of such registration requirements, or (ii) the expiration of the term of the Option as set forth in the applicable Award Agreement. In
addition, unless otherwise provided in a Participant’s Award Agreement, if the immediate sale of any Common Stock received upon exercise of an Option within the applicable post-termination exercise period following the termination of the
Participant’s Continuous Service (other than for Cause) would violate the Company’s insider trading policy, then the Option will not terminate prior to (i) the expiration of a period of months equal to the applicable post-termination
exercise period after the termination of the Participant’s Continuous Service during which the sale of the Common Stock received upon exercise of the Option would not be in violation of the Company’s insider trading policy, or
(ii) the expiration of the permitted term of the Option as set forth in the applicable Award Agreement as determined without giving effect to any termination of Continuous Service. 

(k)    Termination for Cause. Except as explicitly provided otherwise in a Participant’s Award
Agreement or other individual written agreement between the Company or any Affiliate and the Participant, if a Participant’s Continuous Service is terminated for Cause, the Option will terminate immediately upon such Participant’s
termination of Continuous Service, and the Participant will be prohibited from exercising his or her Option from and after the time of such termination of Continuous Service. 

  
 6. 

 (l)    Non-Exempt
Employees. If an Option is granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, the Option will not be first exercisable for any shares of
Common Stock until at least six (6) months following the date of grant of the Option (although the Award may vest prior to such date). Consistent with the provisions of the Worker Economic Opportunity Act, (i) if such non-exempt Employee dies or suffers a Disability, (ii) upon a Corporate Transaction in which such Option is not assumed, continued, or substituted, (iii) upon a Change in Control, or (iv) upon the
Participant’s retirement (as such term may be defined in the Participant’s Award Agreement in another agreement between the Participant and the Company, or, if no such definition, in accordance with the Company’s then current
employment policies and guidelines), the vested portion of any Options and Stock Appreciation Rights may be exercised earlier than six (6) months following the date of grant. The foregoing provision is intended to operate so that any income
derived by a non-exempt employee in connection with the exercise or vesting of an Option will be exempt from his or her regular rate of pay. 

6.    PROVISIONS RELATING TO RESTRICTED STOCK
AND RESTRICTED STOCK UNIT AWARDS. 

(a)    Restricted Stock Awards. A “Restricted Stock Award” is an award of actual
shares of Common Stock that is subject to certain specified restrictions that lapse over the applicable vesting schedule. Each Restricted Stock Award will be subject to the conditions set forth in this Section 6(a), and such other conditions
not inconsistent with the Plan as may be reflected in the applicable Award Agreement. 

(i)    Consideration. A Restricted Stock Award may be awarded in consideration for (A) cash, check,
bank draft or money order payable to the Company, (B) past or future services to the Company or an Affiliate, or (C) any other form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under
applicable law. 
 (ii)    Book Entry. To the extent consistent with the Company’s Bylaws, at the
Board’s election, shares of Common Stock may be (i) held in book entry form subject to the Company’s instructions until any restrictions relating to the Restricted Stock Award lapse; or (ii) evidenced by a certificate, which
certificate will be held in such form and manner as determined by the Board. 
 (iii)    Dividends. An
Award Agreement evidencing a Restricted Stock Award may provide that any dividends paid on Restricted Stock will be subject to the same vesting and forfeiture restrictions as apply to the shares subject to the Restricted Stock Award to which they
relate. 
 (b)    Restricted Stock Unit Awards. A “Restricted Stock Unit
Award” means an unfunded and unsecured promise to deliver shares of Common Stock, cash, other securities or other property, subject to certain restrictions. Each Restricted Stock Unit Award will be subject to the
conditions set forth in this Section 6(b), and such other conditions not inconsistent with the Plan as may be reflected in the applicable Award Agreement. 

(i)    Consideration. At the time of grant of a Restricted Stock Unit Award, the Board will
determine the consideration, if any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award. The consideration to be paid (if any) by the Participant for each share of Common Stock
subject to a Restricted Stock Unit Award may be paid in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under 

  
 7. 

 
applicable law. Unless otherwise determined by the Board at the time of grant, each Restricted Stock Unit Award will be granted in consideration of the Participant’s services to the Company
so that a Participant will not be required to make any payment to the Company (other than services to the Company) with respect to receipt of the Award, the vesting of the Award or the delivery of the Common Stock to be issued in settlement of the
Award. 
 (ii)    Settlement. A Restricted Stock Unit Award may be settled by the delivery of
shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the Award Agreement. 

(iii)    Additional Restrictions. At the time of the grant of a Restricted Stock Unit Award, the Board, as
it deems appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a time after the vesting of such Restricted Stock Unit
Award, subject to compliance with Section 409A of the Code (if applicable). 
 (iv)    Dividend
Equivalents. Dividend equivalents may be credited in respect of shares of Common Stock covered by a Restricted Stock Unit Award, as determined by the Board and contained in the Award Agreement. At the sole discretion of the Board, such dividend
equivalents may be converted into additional shares of Common Stock covered by the Restricted Stock Unit Award in such manner as determined by the Board. Any additional shares covered by the Restricted Stock Unit Award credited by reason of such
dividend equivalents will be subject to all of the same terms and conditions of the underlying Award Agreement to which they relate. 

(v)    Unsecured Obligation. A Restricted Stock Unit Award is an unfunded obligation, and as a holder of a
vested Restricted Stock Unit Award, a Participant will be considered an unsecured creditor of the Company with respect to the Company’s obligation, if any, to issue shares pursuant to the terms of the applicable Award Agreement. A Participant
will not have voting or any other rights as a stockholder of the Company with respect to the shares to be issued pursuant a Restricted Stock Unit Award unless and until such shares are actually issued. Nothing contained in the Plan or any Award
Agreement, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary relationship between a Participant and the Company or any other person. 

7.    OTHER STOCK-BASED AWARDS.
Other forms of Awards valued in whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof (e.g., stock appreciation rights, options with an exercise price less than 100% of the Fair Market
Value of the Common Stock at the time of grant) (an “Other Stock-Based Award”) may be granted either alone or in addition to other types of Awards provided for under the Plan. Subject to the provisions of the Plan, the Board
will have sole and complete authority to determine the persons to whom and the time or times at which such Other Stock-Based Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such
Other Stock-Based Awards and all other terms and conditions of such Other Stock-Based Awards. 
 8.    ADJUSTMENTS
UPON CHANGES IN COMMON STOCK; OTHER CORPORATE EVENTS. 

(a)    Capitalization Adjustments. In the event of a Capitalization Adjustment, the Board will appropriately
and proportionately adjust: (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section 3(a), (ii) the class(es) and maximum number of securities that may be issued pursuant to the exercise of Incentive Stock
Options pursuant to Section 3(c), and (iii) the class(es) and number of securities and price per share of stock subject to outstanding Awards. The Board will make such adjustments, and its determination will be final, binding and
conclusive. 

  
 8. 

 (b)    Dissolution. Except as otherwise provided in the
Award Agreement, in the event of a dissolution or liquidation of the Company, all outstanding Awards (other than Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company’s right of
repurchase) will terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company’s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired
by the Company notwithstanding the fact that the holder of such Award is providing Continuous Service. Conversion of the Company into a limited liability company (or any other pass-through entity) will not be considered a dissolution or liquidation
for purposes of the Plan. 
 (c)    Corporate Transaction. The following provisions will apply to Awards
in the event of a Corporate Transaction (including a transaction that also constitutes a Change in Control) unless otherwise provided in a Participant’s Award Agreement or any other written agreement between the Company or any Affiliate and the
Participant, or unless otherwise expressly provided by the Board at the time of grant of an Award. In the event of a Corporate Transaction, then, notwithstanding any other provision of the Plan, the Board will take one or more of the following
actions with respect to Awards, contingent upon the closing or completion of the Corporate Transaction: 

(i)    arrange for the surviving corporation or acquiring corporation (or the surviving or acquiring
corporation’s parent company) to assume or continue the Award or to substitute a similar stock award for the Award (including, but not limited to, an award to acquire the same consideration paid to the stockholders of the Company pursuant to
the Corporate Transaction); 
 (ii)    arrange for the assignment of any reacquisition or repurchase rights held
by the Company in respect of Common Stock issued pursuant to the Award to the surviving corporation or acquiring corporation (or the surviving or acquiring corporation’s parent company); 

(iii)    accelerate the vesting, in whole or in part, of the Award (and, if applicable, the time at which the Award
may be exercised) to a date prior to the effective time of such Transaction as the Board will determine (or, if the Board will not determine such a date, to the date that is five days prior to the effective date of the Transaction), with such Award
terminating if not exercised (if applicable) at or prior to the effective time of the Corporate Transaction; 

(iv)    arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by the Company
with respect to the Award; 
 (v)    cancel or arrange for the cancellation of the Award, to the extent not
vested prior to the effective time of the Corporate Transaction, in exchange for no consideration ($0) or such cash consideration, if any, as the Board, in its sole discretion, may consider appropriate; and 

(vi)    cancel or arrange for the cancellation of the Award, to the extent not exercised prior to the effective
time of the transaction, in exchange for a payment, in such form as may be determined by the Board, equal to the excess, if any, of (A) the per share amount (or value of property per share) payable to holders of Common Stock in connection with
the Corporate Transaction, over (B) the per share exercise price under the applicable Award, multiplied by the number of vested shares subject to the Award. For clarity, this payment may be $0 if the amount per share (or value of property per
share) payable to the holders of the Common Stock as of the closing of the Corporate Transaction is equal to or less than the per 

  
 9. 

 
share exercise price of the Award. In addition, any escrow, holdback, earnout or similar provisions in the definitive agreement for the Corporate Transaction may apply to such payment to the
holder of the Award to the same extent and in the same manner as such provisions apply to the holders of Common Stock. 
 The Board need not
take the same action or actions with respect to all Awards or portions thereof or with respect to all Participants. The Board may take different actions with respect to the vested and unvested portions of an Award. 

(d)    Change in Control. An Award may be subject to additional acceleration of vesting and exercisability
upon or after a Change in Control as may be provided in the Award Agreement for such Award or as may be provided in any other written agreement between the Company or any Affiliate and the Participant, but in the absence of such provision, no such
acceleration will occur. 
 9.    SECURITIES LAW COMPLIANCE. 

(a)    General. This Plan is intended to be a written compensatory benefit plan within the meaning of
Rule 701 of the Securities Act; however, Awards may be granted under this Plan that do not qualify for exemption under Rule 701. The Company will seek to obtain from each regulatory commission or agency having jurisdiction over the Plan such
authority as may be required to grant Awards and to issue and sell shares of Common Stock upon exercise of the Awards; provided, however, that this undertaking will not require the Company to register under the Securities Act the Plan, any
Award or any Common Stock issued or issuable pursuant to any such Award. A Participant will not be eligible for the grant of an Award or the subsequent issuance of cash or Common Stock pursuant to the Award if such grant or issuance would be in
violation of any applicable securities law. 
 (b)    Representations; Legends. The Board or the Stock
Plan Administrator may, as a condition to the grant of any Award or the exercise of any Option under the Plan, require a Participant to (i) represent in writing that the shares received in connection with such Award are being acquired for
investment and not with a view to distribution and (ii) make such other representations and warranties as are deemed appropriate by counsel to the Company. Each certificate representing shares acquired under the Plan will bear one or more
legends in such form as the Company deems appropriate. 
 10.    TAX MATTERS. 

(a)    Withholding Obligation. Each Participant shall, no later than the date as of which the value of an
Award or of any shares or other amounts received thereunder first becomes includable in the gross income of the Participant, pay to the Company, or make arrangements satisfactory to the Company regarding payment of, amounts sufficient to satisfy
applicable U.S. federal, state, local and international income tax, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items related to the Participant’s
participation in the Plan (the “Tax-Related Items”) and legally applicable to the Participant, if any, which arise in connection with the exercise,
vesting or settlement of such Award, as applicable. Unless otherwise determined by the Board, the Fair Market Value of the Shares will be determined as of the date that the taxes are required to be withheld. The Company’s obligation to deliver
stock certificates (or evidence of book entry) to any Participant is subject to and conditioned on any such tax withholding obligations being satisfied by the Participant. 

(b)    Withholding Authorization. Unless otherwise provided in the Participant’s Award Agreement, the
Board or the Stock Plan Administrator, in its sole discretion and pursuant to such procedures as it may specify from time to time and subject to limitations of applicable law, may require or permit a

  
 10. 

 
Participant to satisfy any applicable withholding obligations for Tax-Related Items, in whole or in part by (without limitation): (i) requiring the
Participant to make a cash payment, (ii) withholding from the Participant’s wages or other cash compensation paid to the Participant by the Company or any Affiliate; (iii) withholding from the Shares otherwise issuable a number of
Shares having an aggregate Fair Market Value equal to all or a portion of the Tax-Related Items to be withheld, (iv) permitting the Participant to deliver to the Company already-owned shares
having an aggregate Fair Market Value equal to the Tax-Related Items to be withheld or (v) withholding from the proceeds of the sale of otherwise deliverable Shares acquired pursuant to an Award either
through a voluntary sale or through a mandatory sale arranged by the Company. The Company may withhold or account for these Tax-Related Items up to (but not in excess of) the maximum permissible statutory tax
rate for the applicable tax jurisdiction. Whenever payments in satisfaction of Awards under this Plan are made in cash, such payment will be net of applicable withholding requirements for Tax-Related Items.

 (c)    Section 409A Compliance. Unless otherwise expressly provided for in an Award Agreement, the Plan
and Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section 409A of the Code, and, to the extent not so exempt, in compliance with
Section 409A of the Code. A Corporate Transaction or Change in Control must also constitute a change in the ownership or effective control of the Company, or in the ownership of a substantial portion of the Company’s assets, within the
meaning of Section 409A of the Code, and the determination of whether there has been a termination of Continuous Service will be made in a manner that is consistent with the definition of “separation from service”, if required to
prevent such payment from being subject to interest, penalties and/or additional tax imposed pursuant to Section 409A of the Code. Unless an Award Agreement specifically provides otherwise, if the shares of Common Stock are publicly traded, and
if a Participant holding an Award that constitutes “deferred compensation” under Section 409A of the Code is a “specified employee” for purposes of Section 409A of the Code, no distribution or payment of any amount that
is due because of a separation from service will be issued or paid before the date that is six months following the date of such Participant’s separation from service or, if earlier, the date of the Participant’s death, unless such
distribution or payment can be made in a manner that complies with Section 409A of the Code, and any amounts so deferred will be paid in a lump sum on the day after such six month period elapses, with the balance paid thereafter on the original
schedule. 
 (d)    No Liability for Taxes. The Company has no duty or obligation to minimize the tax
consequences of an Award to a Participant, and neither the Company nor any of its Officers, Directors, Employees or Affiliates will be liable to a Participant or any other person for any adverse tax consequences in connection with an Award. 

11.    GENERAL PROVISIONS. 

(a)    Vesting. The Board may impose such restrictions on or conditions to the vesting of the Shares subject
to Awards as it deems appropriate. The vesting provisions of individual Awards may vary. Except as otherwise provided in the Award Agreement or an individual agreement with the Participant, vesting under an Award will cease immediately upon
termination of the Participant’s Continuous Service, and the Participant will have no further right, title or interest in such unvested portion of an Award. 

(b)    No Fractional Shares. No fractional shares of Common Stock shall be issued or delivered pursuant to
the Plan. The Committee shall determine whether cash, additional Awards or other securities or property shall be issued or paid in lieu of fractional shares of Common Stock or whether any fractional shares should be rounded, forfeited or otherwise
eliminated. 

  
 11. 

 (c)    Stockholder Rights. No Participant will be deemed
to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to an Award unless and until (i) such Participant has satisfied all requirements for exercise of, or the issuance of shares of
Common Stock under, the Award pursuant to its terms, and (ii) the issuance of the Common Stock subject to such Award has been entered into the books and records of the Company. 

(d)    No Employment or Other Service Rights. The adoption of the Plan and the grant of Awards do not confer
upon any Participant any right to continued employment or service with the Company or any Affiliate. 

(e)    Change in Time Commitment. In the event a Participant’s regular level of time commitment in the
performance of his or her services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time
Employee or takes an extended leave of absence) after the date of grant of any Award to the Participant, the Board has the right in its sole discretion to (x) make a corresponding reduction in the number of shares or cash amount subject to any
portion of such Award that is scheduled to vest or become payable after the date of such change in time commitment, and (y) in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Award. In
the event of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or extended. 

(f)    Execution of Additional Documents; Repurchase Rights. The Company may require a Participant to
execute any additional documents or instruments necessary or desirable, as determined in the sole discretion of the Board or the Stock Plan Administrator, to carry out the purposes or intent of the Award, including any stockholders’ agreement
providing for restrictions on the transferability of Shares acquired under the Plan (such as a right of first refusal, call rights or drag-along rights of the Company and certain of its investors). The Company will also have any repurchase rights
set forth in the Company’s bylaws or any Award Agreement. The Company will not be required to exercise any repurchase right provided in the bylaws, the Plan, any Award Agreement, or other agreement between the Company and a Participant until at
least six (6) months (or such longer or shorter period of time necessary to avoid classification of the Award as a liability for financial accounting purposes) have elapsed following delivery of Shares. 

(g)    Electronic Delivery and Participation. Any reference in the Plan or in an Award Agreement to a
“written” agreement or document will include any agreement or document delivered electronically or posted on the Company’s intranet (or other shared electronic medium controlled by the Company to which the Participant has access). The
form of delivery of any Common Stock (e.g., a stock certificate or electronic entry evidencing such shares) will be determined by the Stock Plan Administrator. 

12.    PLAN TERM; EARLIER TERMINATION OR
SUSPENSION OF THE PLAN. 
 The Board may suspend or terminate the Plan at any
time. Unless terminated sooner by the Board, the Plan will automatically terminate on the day before the tenth (10th) anniversary of the earlier of the date the Plan is adopted by the Board or approved by the stockholders of the Company. No Awards
may be granted under the Plan while the Plan is suspended or after it is terminated. Suspension or termination of the Plan will not materially impair rights and obligations under any Award granted while the Plan is in effect except with the written
consent of the affected Participant or as otherwise permitted in the Plan. 

  
 12. 

 13.    EFFECTIVE DATE OF
PLAN. 
 The Plan will become effective on the date this Plan is adopted by the Board (the “Effective Date”). 

14.    CHOICE OF LAW. 

The law of the State of Delaware will govern all questions concerning the construction, validity and interpretation of this Plan, without
regard to that state’s conflict of laws rules. 
 15.    DEFINITIONS. As used in the Plan, the
following definitions will apply to the capitalized terms indicated below: 

(a)    “Affiliate” means, at the time of determination, any “parent” or
“subsidiary” of the Company as such terms are defined in Rule 405 of the Securities Act. The Board will have the authority to determine the time or times at which “parent” or “subsidiary” status is determined within the
foregoing definition. 
 (b)    “Award” means any right to receive Common Stock granted
under the Plan, including an Incentive Stock Option, a Nonstatutory Stock Option, a Restricted Stock Award, a Restricted Stock Unit Award, or any Other Stock-Based Award. 

(c)    “Award Agreement” means a written agreement between the Company and a Participant
evidencing the terms and conditions of an Award. 
 (d)    “Capitalization Adjustment”
means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation,
reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar
equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible
securities of the Company will not be treated as a Capitalization Adjustment. 

(e)    “Cause” will have the meaning ascribed to such term in any written
agreement between the Participant and the Company or an Affiliate defining such term and, in the absence of such agreement, such term means, with respect to a Participant, the occurrence of any of the following events: (i) such
Participant’s commission of any felony or any crime involving fraud, dishonesty or moral turpitude; (ii) such Participant’s attempted commission of, or participation in, a fraud or act of dishonesty against the Company or an
Affiliate; (iii) such Participant’s intentional, material violation of any contract or agreement between the Participant and the Company or an Affiliate or of any statutory duty owed to the Company or an Affiliate; (iv) such
Participant’s unauthorized use or disclosure of confidential information or trade secrets of the Company or an Affiliate; or (v) such Participant’s gross misconduct. The determination that a termination of the Participant’s
Continuous Service is either for Cause or without Cause will be made by the Company, in its sole discretion. Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of
outstanding Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company or such Participant for any other purpose. 

  
 13. 

 (f)    “Change in Control” means a
Corporate Transaction that also qualifies as a “Deemed Liquidation Event” as defined in the Company’s Amended and Restated Certificate of Incorporation, as may be amended from time to time, and does not otherwise constitute any
of the following (as determined by the Board): (i) a Capitalization Adjustment, (ii) a public offering of the Company’s securities, (iii) a transaction the primary purpose of which is to raise capital for the Company, (iv) a
transaction effected exclusively for the purpose of changing the domicile or corporate form of the Company, or (v) a merger, consolidation or similar transaction involving (directly or indirectly) the Company in which the stockholders of the
Company immediately prior to such transaction continue to hold (directly or indirectly), at least a majority of the combined outstanding voting power of the Company or the surviving entity in such transaction (as applicable) immediately following
such transaction. The definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any Affiliate and the Participant will supersede the foregoing definition with respect to Awards subject to such
agreement; provided, however, that if no definition of Change in Control or any analogous term is set forth in any individual written agreement, the foregoing definition will apply. 

(g)    “Code” means the Internal Revenue Code of 1986, as amended, including any applicable
regulations and guidance thereunder. 
 (h)    “Common Stock” means the common stock of
the Company. 
 (i)    “Consultant” means any person, including an advisor, who is
(i) engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii) serving as a member of the board of directors of an Affiliate and is compensated for such services. However,
service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a “Consultant” for purposes of the Plan.  

(j)    “Continuous Service” means that the Participant’s service with the Company or
an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Consultant or Director or a change in
the entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant’s service with the Company or an Affiliate, will not terminate a Participant’s Continuous Service;
provided, however, that if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, in its sole discretion, such Participant’s Continuous Service will be considered to
have terminated on the date such Entity ceases to qualify as an Affiliate. 
 (k)    “Corporate
Transaction” means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events: 

(i)    a sale or other disposition of all or substantially all, as determined by the Board, in its sole
discretion, of the consolidated assets of the Company and its Subsidiaries; 
 (ii)    a sale or other
disposition of more than 50% of the outstanding securities of the Company; 
 (iii)    a merger, consolidation or
similar transaction following which the Company is not the surviving corporation; or 

  
 14. 

 (iv)    a merger, consolidation or similar transaction following
which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction
into other property, whether in the form of securities, cash or otherwise. 

(l)    “Director” means a member of the Board. 

(m)    “Disability” means, with respect to a Participant, the inability of such Participant
to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuous period of not less than twelve
(12) months, as provided in Sections 22(e)(3) and 409A(a)(2)(c)(i) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances. 

(n)    “Employee” means any person employed by the Company or an Affiliate. However,
service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an “Employee” for purposes of the Plan. 

(o)    “Entity” means a corporation, partnership, limited liability company or other
entity. 
 (p)    “Exchange Act” means the Securities Exchange Act of 1934, as amended,
and the rules and regulations promulgated thereunder. 
 (q)    “Fair Market Value”
means, as of any date, the value of the Common Stock determined by the Board in compliance with Section 409A of the Code or, in the case of an Incentive Stock Option, in compliance with Section 422 of the Code. 

(r)    “Incentive Stock Option” or “ISO” means an Option that is
intended to be, and qualifies as, an “incentive stock option” within the meaning of Section 422 of the Code. 

(s)    “Nonstatutory Stock Option” or “NSO” means any Option
granted pursuant to the Plan that by its terms does not qualify or is not intended to qualify as an Incentive Stock Option. Nonstatutory Stock Options are also sometimes referred to as “Nonqualified Options” or “NQSOs.” 

(t)    “Officer” means any person designated by the Company as an officer. 

(u)    “Participant” means a person to whom an Award is granted pursuant to the Plan or, if
applicable, such other person who holds an outstanding Award. 
 (v)    “Securities Act”
means the Securities Act of 1933, as amended. 
 (w)    “Ten Percent Stockholder” means a
person who owns (or is deemed to own pursuant to Section 424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate. 

* * * * * * * 

  
 15. 

 Plan History: 
  

			
	Date adopted by the Board of Directors:	  	June 25, 2018
		
	Date approved by the Stockholders:	  	July 17, 2018
		
	Date amended by the Board of Directors	  	July 31, 2018
		
	Date approved by the Stockholders	  	August 10, 2018

  
 16. 

 ALLOGENE THERAPEUTICS, INC. 

STOCK OPTION GRANT NOTICE 

(AMENDED AND RESTATED 2018 EQUITY INCENTIVE PLAN)

 ALLOGENE THERAPEUTICS, INC. (the “Company”), pursuant to its Amended and
Restated 2018 Equity Incentive Plan (the “Plan”), hereby grants to Participant an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and
conditions as set forth in this Stock Option Grant Notice, the Option Terms and Conditions, and the Plan, all of which are attached hereto and incorporated herein in their entirety. This Stock Option Grant Notice and the Option Terms and Conditions
are collectively referred to as the “Option Agreement.” Capitalized terms not explicitly defined in this Agreement but defined in the Plan will have the same definitions as in the Plan. If there is any conflict
between the terms in this Agreement and the Plan, the terms of the Plan will control. 
  

					
	Participant:	 	  
	 	
	Date of Grant:	 	  
	 	
	Vesting Commencement Date:	 	  
	 	
	Number of Shares Subject to Option:	 	  
	 	
	Exercise Price (Per Share):	 	  
	 	
	Total Exercise Price:	 	  
	 	
	Expiration Date:	 	  
	 	

  

					
	Type of Grant:	  	 ☐  Incentive Stock Option1
	  	☐  Nonstatutory Stock Option
			
	Exercise Schedule:	  	☐  Same as Vesting Schedule	  	☐  Early Exercise Permitted
	  
 Vesting Schedule:
	  	  
 [Sample of standard vesting. One-fourth (1/4th) of the shares vest one year after the Vesting Commencement Date; the balance of the shares vest in a series of 36 successive equal monthly
installments measured from the first anniversary of the Vesting Commencement Date, subject to Participant’s Continuous Service as of each such date.]

 Additional Terms/Acknowledgements: Participant acknowledges receipt of, and understands and agrees to, this Agreement
and the Plan. Participant acknowledges and agrees that this Option Agreement may not be modified, amended or revised except as provided in the Plan. Participant further acknowledges that as of the Date of Grant, this Option Agreement, and the
Plan set forth the entire understanding between Participant and the Company regarding this option award and supersede all prior oral and written agreements, promises and/or representations on that subject with the exception of Awards previously
granted and delivered to Participant. 
 This Stock Option Grant Notice and any notices, agreements or other documents related thereto may be executed in
two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature
complying with the U.S. federal ESIGN Act of 
  

	1 	 If this is an Incentive Stock Option, it (plus other outstanding Incentive Stock Options) cannot be first
exercisable for more than $100,000 in value (measured by exercise price) in any calendar year. Any excess over $100,000 is a Nonstatutory Stock Option. 

 
2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be
valid and effective for all purposes. 
 By accepting this option, you consent to receive such documents by electronic delivery and to participate in the
Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company. 

 

									
	ALLOGENE THERAPEUTICS, INC.	 		 	PARTICIPANT:
					
	By:	 	  
	 		 		 	  

		 	Signature	 		 		 	Signature
					
	Title:	 	  
	 		 	Email:	 	  

	Email:	 	  
	 		 	Date:	 	  

	Date:	 	  
	 		 		 	

  

	ATTACHMENTS:    Option	 Terms and Conditions 

                          
      Amended and Restated 2018 Equity Incentive Plan 

 ATTACHMENT I 

OPTION TERMS AND CONDITIONS 

 ATTACHMENT II 

AMENDED AND RESTATED 2018 EQUITY INCENTIVE PLAN 

 ALLOGENE THERAPEUTICS, INC. 

AMENDED AND RESTATED 

2018 EQUITY INCENTIVE PLAN 

OPTION TERMS AND CONDITIONS 

(Incentive Stock Option or Nonstatutory Stock Option) 

As reflected by your Stock Option Grant Notice (the “Grant Notice”) and these Option Terms and Conditions (together,
this “Option Agreement”), ALLOGENE THERAPEUTICS, INC. (the “Company”) has granted you an option under its Amended and Restated 2018 Equity Incentive
Plan (the “Plan”) to purchase the number of shares of the Company’s Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice. The option is granted to you effective as of the date
of grant set forth in the Grant Notice (the “Date of Grant”). 
 The details of your option, in addition to those
set forth in the Grant Notice and the Plan, are as follows: 
 1.    GOVERNING
PLAN DOCUMENT. Your option is subject to all the provisions of the Plan, including but not limited to the provisions in the Plan regarding the impact of any Capitalization Adjustment, Dissolution or Corporate
Transaction. Your option is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan. If there is any conflict between the terms in this Option Agreement
and the Plan, the terms of the Plan will control. Capitalized terms not explicitly defined in this Option Agreement but defined in the Plan will have the same definitions as in the Plan. 

2.    VESTING. Your option will vest as provided in your Grant Notice. Vesting
will cease upon the termination of your Continuous Service. 
 3.    EXERCISE. 

(a)    General. You may exercise the vested portion of your option during its term by delivering a
Notice of Exercise (in the form designated by the Company), together with payment of the exercise price and applicable withholding taxes, and such additional documents as the Company may then require (including, without limitation, any
stockholders’ agreement between the Company and certain of its stockholders) to the Stock Plan Administrator in accordance with the option exercise procedures established by the Stock Plan Administrator, which may include an electronic
submission. Certain terms of the Plan may also restrict or prohibit your ability to exercise your option during certain periods. 

(b)    Exercise Prior to Vesting (“Early Exercise”). If permitted in your Grant Notice
(i.e., the “Exercise Schedule” indicates “Early Exercise Permitted”) and subject to the provisions of your option, you may elect at any time that is both (i) during the period of your Continuous Service and
(ii) during the term of your option, to exercise all or part of your option, including the unvested portion of your option by completing and delivering an Early Exercise Notice and Stock Purchase Agreement (in the
form designated by the Company). A partial exercise of your option will be deemed to cover first vested shares of Common Stock and then the earliest vesting installment of unvested shares of Common Stock. If your option is an Incentive Stock Option,
then, to the extent that the aggregate Fair Market Value (determined at the Date of Grant) of the shares of Common Stock with respect to which your option plus all other Incentive Stock Options you hold are exercisable for the first
time by you during any calendar year (under all plans of the Company and its Affiliates) exceeds $100,000, your option(s) or portions thereof that exceed such limit (according to the order in which they were granted) will be treated as Nonstatutory
Stock Options. 

  
 1. 

 4.    METHOD OF
PAYMENT. You may always pay the Option exercise price in cash or by check, bank draft or money order. At the sole discretion of the Company at the time of exercise, you may be permitted to pay the Option exercise price
pursuant to another payment method permitted by the Plan, subject to the restrictions specified in the Plan. 

5.    WHOLE SHARES. You may exercise your option only for whole
shares of Common Stock. 
 6.    TERM. You may not exercise your option
before the Date of Grant or after the expiration of the option’s term. Except as set forth in your Grant Notice, the term of your option expires, subject to the provisions of Section 5 of the Plan, upon the earliest of the following: 

(a)    immediately upon the termination of your Continuous Service for Cause; 

(b)    three (3) months after the termination of your Continuous Service for any reason other than Cause,
Disability or death; 
 (c)    12 months after the termination of your Continuous Service due to your Disability;

 (d)    18 months after your death if you die either during your Continuous Service (or during the periods
provided in clauses (b) and (c) above); 
 (e)    the Expiration Date indicated in your Grant Notice; or

 (f)    the day before the 10th anniversary of the Date of Grant. 

Notwithstanding the foregoing, your option may also be terminated earlier in connection with a Corporate Transaction, as provided in the Plan.

 If your option is an Incentive Stock Option, note that to obtain the federal income tax advantages associated with an Incentive Stock
Option, the Code requires that at all times beginning on the Date of Grant and ending on the day three months before the date of your option’s exercise, you must be an employee of the Company or an Affiliate, except in the event of your death
or Disability. The Company has provided for extended exercisability of your option under certain circumstances for your benefit but cannot guarantee that your option will necessarily be treated as an Incentive Stock Option if you continue to provide
services to the Company or an Affiliate as a Consultant or Director after your employment terminates or if you otherwise exercise your option more than three months after the date your employment with the Company or an Affiliate terminates. 

7.    TRANSFERABILITY. Except as otherwise provided in the Plan, your option
is not transferable, except by will or by the laws of descent and distribution, and is exercisable during your life only by you. 

8.    MARKET STAND-OFF.
By exercising your option you agree that you will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect
to any shares of Common Stock or other securities of the Company held by you, for a period of 180 days following the effective 

  
 2. 

 
date of a registration statement of the Company filed under the Securities Act or such longer period as the underwriters or the Company will request to facilitate compliance with FINRA Rule 2711
or NYSE Member Rule 472 or any successor or similar rules or regulation(the “Lock-Up Period”); provided, however, that nothing contained in this section will prevent the exercise
of a repurchase option, if any, in favor of the Company during the Lock-Up Period. You further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the
underwriters that are consistent with the foregoing or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to your shares of Common Stock until
the end of such period. You also agree that any transferee of any shares of Common Stock (or other securities) of the Company held by you will be bound by this section. The underwriters of the Company’s stock are intended third party
beneficiaries of this section and will have the right, power and authority to enforce the provisions hereof as though they were a party hereto. 

9.    RIGHT OF FIRST REFUSAL.
Shares of Common Stock that you acquire upon exercise of your option are subject to any right of first refusal that may be described in the Company’s bylaws in effect at such time the Company elects to exercise its right; provided,
however, that if there is no right of first refusal described in the Company’s bylaws at such time, the right of first refusal described below will apply. The Company’s right of first refusal will expire on the first date upon which
any security of the Company is listed (or approved for listing) upon notice of issuance on a national securities exchange or quotation system (the “Listing Date”). 

(a)    Prior to the Listing Date, you may not validly Transfer (as defined below) any shares of Common Stock
acquired upon exercise of your option, or any interest in such shares, unless such Transfer is made in compliance with the following provisions: 

(i)    Before there can be a valid Transfer of any shares of Common Stock or any interest therein, the record
holder of the shares of Common Stock to be transferred (the “Offered Shares”) will give written notice (by registered or certified mail) to the Company. Such notice will specify the identity of the proposed transferee, the
cash price offered for the Offered Shares by the proposed transferee (or, if the proposed Transfer is one in which the holder will not receive cash, such as an involuntary transfer, gift, donation or pledge, the holder will state that no purchase
price is being proposed), and the other terms and conditions of the proposed Transfer. The date such notice is mailed will be hereinafter referred to as the “Notice Date” and the record holder of the Offered Shares will be
hereinafter referred to as the “Offeror.” If, from time to time, there is any stock dividend, stock split or other change in the character or amount of any of the outstanding Common Stock which is subject to the provisions of
your option, then in such event any and all new, substituted or additional securities to which you are entitled by reason of your ownership of the shares of Common Stock acquired upon exercise of your option will be immediately subject to the
Company’s Right of First Refusal (as defined below) with the same force and effect as the shares subject to the Right of First Refusal immediately before such event. 

(ii)    For a period of 30 calendar days after the Notice Date, or such longer period as may be required to avoid
the classification of your option as a liability for financial accounting purposes, the Company will have the option to purchase all (but not less than all) of the Offered Shares at the purchase price and on the terms set forth in this section (the
Company’s “Right of First Refusal”). In the event that the proposed Transfer is one involving no payment of a purchase price, the purchase price will be deemed to be the Fair Market Value of the Offered Shares as
determined in good faith by the Board in its discretion. The Company may exercise its Right of First Refusal by mailing (by registered or certified mail) written notice of exercise of its Right of First Refusal to the Offeror prior to the end of
said 30 days (including any extension required to avoid classification of the option as a liability for financial accounting purposes). 

  
 3. 

 (iii)    The price at which the Company may purchase the Offered
Shares pursuant to the exercise of its Right of First Refusal will be the cash price offered for the Offered Shares by the proposed transferee, or the Fair Market Value as determined by the Board in the event no purchase price is involved. To the
extent consideration other than cash is offered by the proposed transferee, the Company will not be required to pay any additional amounts to the Offeror other than the cash price offered (or the Fair Market Value, if applicable). The Company’s
notice of exercise of its Right of First Refusal will be accompanied by full payment for the Offered Shares and, upon such payment by the Company, the Company will acquire full right, title and interest to all of the Offered Shares. 

(iv)    If, and only if, the Right of First Refusal is not exercised, the Transfer proposed in the notice may take
place; provided, however, that such Transfer must, in all respects, be exactly as proposed in said notice except that such Transfer may not take place either before the 10th calendar day
after the expiration of the 30 day option exercise period or after the ninetieth 90th calendar day after the expiration of the 30 day option exercise period, and if such Transfer has not taken
place prior to said 90th day, such Transfer may not take place without once again complying with this section. The timing periods in this section will be adjusted to include any extension required
to avoid the classification of your option as a liability for financial accounting purposes. 
 (b)    As used in
this Option Agreement, the term “Transfer” means any sale, encumbrance, pledge, gift or other form of disposition or transfer of shares of Common Stock or any legal or equitable interest therein; provided, however,
that the term Transfer does not include a transfer of such shares or interests by will or intestacy to your Immediate Family (as defined below). In such case, the transferee or other recipient will receive and hold the shares of Common Stock so
transferred subject to the provisions of this section, and there will be no further transfer of such shares except in accordance with the terms of this Option Agreement. As used herein, the term “Immediate Family” will mean
your spouse, the lineal descendant or antecedent, father, mother, brother or sister, child, adopted child, grandchild or adopted grandchild of you or your spouse, or the spouse of any child, adopted child, grandchild or adopted grandchild of you or
your spouse. 
 (c)    None of the shares of Common Stock purchased on exercise of your option will be
transferred on the Company’s books nor will the Company recognize any such Transfer of any such shares or any interest therein unless and until all applicable provisions of this section have been complied with in all respects. The certificates
of stock evidencing shares of Common Stock purchased on exercise of your option will bear an appropriate legend referring to the transfer restrictions imposed by this section. 

(d)    To ensure that the shares subject to the Company’s Right of First Refusal will be available for
repurchase by the Company, the Company may require you to deposit the certificates evidencing the shares that you purchase upon exercise of your option with an escrow agent designated by the Company under the terms and conditions of an escrow
agreement approved by the Company. If the Company does not require such deposit as a condition of exercise of your option, the Company reserves the right at any time to require you to so deposit the certificates in escrow. As soon as practicable
after the expiration of the Company’s Right of First Refusal, the agent will deliver to you the shares and any other property no longer subject to such restriction. In the event the shares and any other property held in escrow are subject to
the Company’s exercise of its Right of First Refusal, the notices required to be given to you will be given to the escrow agent, and any payment required to be given to you will be given to the escrow agent. Within 30 days after payment by the
Company for the Offered Shares, the escrow agent will deliver the Offered Shares that the Company has repurchased to the Company and will deliver the payment received from the Company to you. 

  
 4. 

 10.    OPTION NOT
A SERVICE CONTRACT. Your option is not an employment or service contract, and nothing in your option will be deemed to create in any way whatsoever any obligation on your part to
continue in the employ of the Company or an Affiliate, or of the Company or an Affiliate to continue your employment. In addition, nothing in your option will obligate the Company or an Affiliate, their respective stockholders, boards of directors,
officers or employees to continue any relationship that you might have as a Director or Consultant for the Company or an Affiliate. 

11.    WITHHOLDING OBLIGATIONS. You may not exercise your
option unless the applicable withholding obligations for Tax-Related Items are satisfied. As further provided in the Plan, at the time you exercise your option, in whole or in part, or at any time thereafter
as requested by the Company, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for, any sums required to satisfy the withholding obligations, if any, which arise in
connection with your option. 
 12.    TAX CONSEQUENCES. You
hereby agree that the Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities. You will not make any claim against the Company, or any of its Officers,
Directors, Employees or Affiliates related to tax liabilities arising from your option or your other compensation. In particular, you acknowledge that this option is exempt from Section 409A of the Code only if the exercise price per share
specified in the Grant Notice is at least equal to the “fair market value” per share of the Common Stock on the Date of Grant and there is no other impermissible deferral of compensation associated with the option. Because the Common Stock
is not traded on an established securities market, the Fair Market Value is determined by the Board, perhaps in consultation with an independent valuation firm retained by the Company. You acknowledge that there is no guarantee that the Internal
Revenue Service will agree with the valuation as determined by the Board, and you will not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates in the event that the Internal Revenue Service asserts that the
valuation determined by the Board is less than the “fair market value” as subsequently determined by the Internal Revenue Service. 

13.    NOTICES. Any notices provided for in your option or the Plan will be
given in writing (including electronically) and will be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five days after deposit in the United States mail, postage prepaid, addressed to you at
the last address you provided to the Company. The Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this option by electronic means or to request your consent to participate in the Plan by
electronic means. By accepting this option, you consent to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the
Company or another third party designated by the Company. 

  
 5. 

 ALLOGENE THERAPEUTICS, INC. 

NOTICE OF EXERCISE 

(for exercise of vested options only) 

Allogene Therapeutics, Inc. 
 210 East Grand Avenue 

South San Francisco, CA 94080 
 Date of Exercise:
                     
 This constitutes
notice to ALLOGENE THERAPEUTICS, INC. (the “Company”) under my stock option that I elect to purchase the below number of shares of Common Stock of the Company
(the “Shares”) for the price set forth below. 
  

									
			
	 Type of option (check one):
	  	 	Incentive ☐	 	 	 	Nonstatutory ☐	 
			
	 Stock option dated:
	  	 	                        	 	 	 	                        	 
			
	 Number of Shares as to which option is exercised:
	  	 	                        	 	 	 	                        	 
			
	 Certificates to be issued in name of:
	  	 	                        	 	 	 	                        	 
			
	 Total exercise price:
	  	 	$                    	 	 	 	$                    	 
			
	 Cash payment delivered herewith:
	  	 	$                    	 	 	 	$                    	 

 By this exercise, I agree (i) to provide such additional documents as you may require pursuant to the
terms of the Amended and Restated 2018 Equity Incentive Plan, (ii) to provide for the payment by me to you (in the manner designated by you) of your withholding obligation, if any, relating to the exercise of this option, and (iii) if this
exercise relates to an incentive stock option, to notify you in writing within 15 days after the date of any disposition of any of the Shares issued upon exercise of this option that occurs within two years after the date of grant of this option or
within one year after such Shares are issued upon exercise of this option. 
 I further agree that this Notice of Exercise may be delivered
via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and shall be deemed to have been
duly and validly delivered and be valid and effective for all purposes. 
 I hereby make the following certifications and representations
with respect to the number of Shares listed above, which are being acquired by me for my own account upon exercise of the option as set forth above: 

I acknowledge that the Shares have not been registered under the Securities Act of 1933, as amended (the “Securities
Act”), and are deemed to constitute “restricted securities” under Rule 701 and Rule 144 promulgated under the Securities Act. I warrant and represent to the Company that I have no present intention of distributing or selling
said Shares, except as permitted under the Securities Act and any applicable state securities laws. I further acknowledge that I will not be able to resell the Shares for 

 
at least 90 days after the stock of the Company becomes publicly traded (i.e., subject to the reporting requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934)
under Rule 701 and that more restrictive conditions apply to affiliates of the Company under Rule 144. 
 I further acknowledge and agree
that, except for such information as required to be delivered to me by the Company pursuant to the option or the Plan (if any), I will have no right to receive any information from the Company by virtue of the grant of the option or the purchase of
shares of Common Stock through exercise of the option, ownership of such shares of Common Stock, or as a result of my being a holder of record of stock of the Company. Without limiting the foregoing, to the fullest extent permitted by law, I hereby
waive all inspection rights under Section 220 of the Delaware General Corporation Law and all such similar information and/or inspection rights that may be provided under the law of any jurisdiction, or any federal, state or foreign regulation,
that are, or may become, applicable to the Company or the Company’s capital stock (the “Inspection Rights”). I hereby covenant and agree never to directly or indirectly commence, voluntarily aid in any way, prosecute,
assign, transfer, or cause to be commenced any claim, action, cause of action, or other proceeding to pursue or exercise the Inspection Rights. 

I further agree that, if required by the Company (or a representative of the underwriters) in connection with the first underwritten
registration of the offering of any securities of the Company under the Securities Act, the Shares may be subject to certain transfer restrictions during the Lock-Up Period as provided in Section 8 of the
Option Terms and Conditions. I further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give further effect thereto.
In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to securities subject to the foregoing restrictions until the end of such period. 

I further acknowledge that all certificates representing any of the Shares subject to the provisions of the option shall have endorsed thereon
appropriate legends reflecting the foregoing limitations, as well as any legends reflecting restrictions pursuant to the Company’s Certificate of Incorporation, Bylaws and/or applicable securities laws. 

 
  

			
	
Very truly yours,                
                                       

		
		 	  

		 	(Signature)
		
		 	  

		 	Name (Please Print)
		
	Address of Record:	 	  

		 	  

		 	  

		
	Email:	 	  

 ALLOGENE THERAPEUTICS, INC. 

EARLY EXERCISE NOTICE AND STOCK PURCHASE
AGREEMENT 
 (AMENDED AND RESTATED 2018 EQUITY
INCENTIVE PLAN) 
 THIS AGREEMENT is made by and
between ALLOGENE THERAPEUTICS, INC., a Delaware corporation (the “Company”), and the individual designated on the signature page hereto as a Purchaser
(“Purchaser”). 
 Purchaser holds a stock option dated
                     to purchase shares of common stock (“Common Stock”) of the Company (the
“Option”) pursuant to the Company’s Amended and Restated 2018 Equity Incentive Plan (the “Plan”). Purchaser wishes to take advantage of the early exercise provision of the Option and therefore to
enter into this Agreement. 
 The parties agree as follows: 

1.    INCORPORATION OF PLAN AND
OPTION BY REFERENCE. This Agreement is subject to all of the terms and conditions as set forth in the Plan and the Option. If there is a conflict between the terms of this Agreement and/or the Option
and the terms of the Plan, the terms of the Plan shall control. If there is a conflict between the terms of this Agreement and the terms of the Option, the terms of the Option shall control. Defined terms not explicitly defined in this Agreement but
defined in the Plan or the Option shall have the same definitions as provided in the Plan or the Option, as applicable. 

2.    PURCHASE AND SALE OF COMMON
STOCK. 
 (a)    Agreement to Purchase and Sell Common Stock. Purchaser hereby
agrees to purchase from the Company, and the Company hereby agrees to sell to Purchaser, shares of the Common Stock of the Company in accordance with the Notice of Exercise duly executed by Purchaser and attached hereto as Exhibit A. 

(b)    Closing. The closing hereunder, including payment for and delivery of the Common Stock, shall occur
at the offices of the Company immediately following the execution of this Agreement, or at such other time and place as the parties may mutually agree; provided, however, that if stockholder approval of the Plan is required before the Option
may be exercised, then the Option may not be exercised, and the closing shall be delayed, until such stockholder approval is obtained. If such stockholder approval is not obtained within the time limit specified in the Plan, then this Agreement
shall be null and void. 
 3.    UNVESTED SHARE REPURCHASE
OPTION. 
 (a)    Repurchase Option. In the event Purchaser’s Continuous Service
terminates, then the Company shall have an irrevocable option (the “Repurchase Option”) for a period of six months after said termination (or in the case of shares issued upon exercise of the Option after such date of
termination, within six months after the date of the exercise), or such longer period as may be agreed to by the Company and Purchaser (the “Repurchase Period”), to repurchase from Purchaser or Purchaser’s personal
representative, as the case may be, those shares that Purchaser received pursuant to the exercise of the Option that have not as yet vested as of such termination date in accordance with the Vesting Schedule indicated on Purchaser’s Stock
Option Grant Notice (the “Unvested Shares”). 
 (b)    Share Repurchase
Price. The Company may repurchase all or any of the Unvested Shares at the lower of (i) the Fair Market Value of the such shares (as determined under the Plan) on the date of repurchase, or (ii) the price equal to
Purchaser’s Exercise Price for such shares as indicated on Purchaser’s Stock Option Grant Notice. 

 (c)    Exercise of Repurchase Option. The Repurchase
Option shall be exercised by written notice signed by such person as designated by the Company, and delivered or mailed as provided herein. Such notice shall identify the number of shares of Common Stock to be purchased and shall notify Purchaser of
the time, place and date for settlement of such purchase, which shall be scheduled by the Company within the term of the Repurchase Option set forth above. In addition, the Company shall be deemed to have exercised the Repurchase Option as of the
last day of the Repurchase Period, unless an officer of the Company notifies the holder of the Unvested Shares during the Repurchase Period in writing (delivered or mailed as provided herein) that the Company expressly declines to exercise its
Repurchase Option for some or all of the Unvested Shares. The Company shall be entitled to pay for any shares of Common Stock purchased pursuant to its Repurchase Option at the Company’s option in cash or by offset against any indebtedness
owing to the Company by Purchaser (including without limitation any promissory note given in payment for the Common Stock), or by a combination of both. Upon exercise of the Repurchase Option and payment of the purchase price in any of the ways
described above, the Company shall become the legal and beneficial owner of the Common Stock being repurchased and all rights and interest therein or related thereto, and the Company shall have the right to transfer to its own name the Common Stock
being repurchased by the Company, without further action by Purchaser. 
 4.    CAPITALIZATION
ADJUSTMENTS TO COMMON STOCK. In the event of a Capitalization Adjustment, then any and all new, substituted or additional securities or other property to which Purchaser is
entitled by reason of Purchaser’s ownership of Common Stock shall be immediately subject to the Repurchase Option and be included in the word “Common Stock” for all purposes of the Repurchase Option with the same force and effect as
the shares of the Common Stock presently subject to the Repurchase Option, but only to the extent the Common Stock is, at the time, covered by such Repurchase Option. While the total Option Price shall remain the same after each such event, the
Option Price per share of Common Stock upon exercise of the Repurchase Option shall be appropriately adjusted. 

5.    CORPORATE TRANSACTIONS. In the event of a Corporate Transaction, then
the Repurchase Option may be assigned by the Company to the successor of the Company (or such successor’s parent company), if any, in connection with such Corporate Transaction. To the extent the Repurchase Option remains in effect following
such Corporate Transaction, it shall apply to the new capital stock or other property received in exchange for the Common Stock in consummation of the Corporate Transaction, but only to the extent the Common Stock was at the time covered by such
right. Appropriate adjustments shall be made to the price per share payable upon exercise of the Repurchase Option to reflect the Corporate Transaction upon the Company’s capital structure; provided, however, that the aggregate price
payable upon exercise of the Repurchase Option shall remain the same. 
 6.    ESCROW
OF UNVESTED COMMON STOCK. As security for Purchaser’s faithful performance of the terms of this Agreement and to insure the availability for delivery
of Purchaser’s Common Stock upon exercise of the Repurchase Option herein provided for, Purchaser agrees, at the closing hereunder, to deliver to and deposit with the Secretary of the Company or the Secretary’s designee (“Escrow
Agent”), as Escrow Agent in this transaction, three stock assignments duly endorsed (with date and number of shares blank) in the form attached hereto as Exhibit B, together with a certificate or certificates evidencing all of the
Common Stock subject to the Repurchase Option; said documents are to be held by the Escrow Agent and delivered by said Escrow Agent pursuant to the Joint Escrow Instructions of the Company and Purchaser set forth in Exhibit C, attached hereto and
incorporated by this reference, which instructions also shall be delivered to the Escrow Agent at the closing hereunder. 

 7.    STOCKHOLDER
RIGHTS. Subject to the provisions of the Option, Purchaser shall exercise all rights and privileges of a stockholder of the Company with respect to the shares deposited in escrow. Purchaser shall be
deemed to be the holder of the shares for purposes of receiving any dividends that may be paid with respect to such shares and for purposes of exercising any voting rights relating to such shares, even if some or all of such shares have not yet
vested and been released from the Company’s Repurchase Option. 
 8.    LIMITATIONS
ON TRANSFER. In addition to any other limitation on transfer created by applicable securities laws, Purchaser shall not sell, assign, hypothecate, donate, encumber or otherwise dispose
of any interest in the Common Stock while the Common Stock is subject to the Repurchase Option. After any Common Stock has been released from the Repurchase Option, Purchaser shall not sell, assign, hypothecate, donate, encumber or otherwise dispose
of any interest in the Common Stock except in compliance with the provisions herein and applicable securities laws. Furthermore, the Common Stock shall be subject to any right of first refusal in favor of the Company or its assignees or other
transfer restrictions that may be contained in the Company’s Bylaws. 
 9.    RESTRICTIVE
LEGENDS. All certificates representing the Common Stock shall have endorsed thereon legends in substantially the following forms (in addition to any other legend which may be required by other
agreements between the parties hereto): 
 (a)    “THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO
AN OPTION SET FORTH IN AN AGREEMENT BETWEEN THE COMPANY AND THE REGISTERED HOLDER, OR SUCH HOLDER’S PREDECESSOR IN INTEREST, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THIS COMPANY. ANY TRANSFER OR ATTEMPTED TRANSFER OF ANY SHARES
SUBJECT TO SUCH OPTION IS VOID WITHOUT THE PRIOR EXPRESS WRITTEN CONSENT OF THE COMPANY.” 

(b)    “THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933
AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER SAID ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT
REQUIRED.” 
 (c)    “THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A RIGHT OF FIRST
REFUSAL OPTION IN FAVOR OF THE COMPANY AND/OR ITS ASSIGNEE(S) AS PROVIDED IN AN AGREEMENT WITH THE COMPANY.” 

(d)    “THE SHARES REPRESENTED BY THIS CERTIFICATE WERE ISSUED PURSUANT TO THE EXERCISE OF [AN INCENTIVE
STOCK OPTION/ A NONSTATUTORY STOCK OPTION].” 
 (e)    “THE SHARES REPRESENTED BY THIS CERTIFICATE
ARE SUBJECT TO A TRANSFER RESTRICTION, AS PROVIDED IN THE BYLAWS OF THE COMPANY.” 
 (f)    Any legend
required by appropriate blue sky officials. 
 10.    INVESTMENT
REPRESENTATIONS. In connection with the purchase of the Common Stock, Purchaser represents to the Company the following: 

 (a)    Purchaser is aware of the Company’s business affairs
and financial condition and has acquired sufficient information about the Company to reach an informed and knowledgeable decision to acquire the Common Stock. Purchaser is acquiring the Common Stock for investment for Purchaser’s own account
only and not with a view to, or for resale in connection with, any “distribution” thereof within the meaning of the Securities Act. 

(b)    Purchaser understands that the Common Stock has not been registered under the Securities Act by reason of a
specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of Purchaser’s investment intent as expressed herein. 

(c)    Purchaser further acknowledges and understands that the Common Stock must be held indefinitely unless the
Common Stock is subsequently registered under the Securities Act or an exemption from such registration is available. Purchaser further acknowledges and understands that the Company is under no obligation to register the Common Stock. Purchaser
understands that the certificate evidencing the Common Stock will be imprinted with a legend that prohibits the transfer of the Common Stock unless the Common Stock is registered or such registration is not required in the opinion of counsel for the
Company. 
 (d)    Purchaser is familiar with the provisions of Rules 144 and 701, under the Securities Act,
as in effect from time to time, which, in substance, permit limited public resale of “restricted securities” acquired, directly or indirectly, from the issuer thereof (or from an affiliate of such issuer), in a non-public offering subject to the satisfaction of certain conditions. Rule 701 provides that if the issuer qualifies under Rule 701 at the time of issuance of the securities, such issuance will be exempt from
registration under the Securities Act. In the event the Company becomes subject to the reporting requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the securities exempt under Rule 701 may be sold by Purchaser 90
days thereafter, subject to the satisfaction of certain of the conditions specified by Rule 144 and the market stand-off provision described in Purchaser’s Stock Option Agreement. 

(e)    In the event that the sale of the Common Stock does not qualify under Rule 701 at the time of purchase,
then the Common Stock may be resold by Purchaser in certain limited circumstances subject to the provisions of Rule 144, which requires, among other things: (i) the availability of certain public information about the Company, and (ii) the
resale occurring following the required holding period under Rule 144 after Purchaser has purchased, and made full payment of (within the meaning of Rule 144), the securities to be sold. 

(f)    Purchaser further understands that at the time Purchaser wishes to sell the Common Stock there may be no
public market upon which to make such a sale, and that, even if such a public market then exists, the Company may not be satisfying the current public current information requirements of Rule 144 or 701, and that, in such event, Purchaser would be
precluded from selling the Common Stock under Rule 144 or 701 even if the minimum holding period requirement had been satisfied. 

(g)    Purchaser further warrants and represents that Purchaser has either (i) preexisting personal or
business relationships, with the Company or any of its officers, directors or controlling persons, or (ii) the capacity to protect his own interests in connection with the purchase of the Common Stock by virtue of the business or financial
expertise of Purchaser or of professional advisors to Purchaser who are unaffiliated with and who are not compensated by the Company or any of its affiliates, directly or indirectly. Purchaser further warrants and represents that Purchaser’s
purchase the Common Stock was not accomplished by the publication of any advertisement. 

 11.    SECTION 83(b)
ELECTION. Purchaser understands that Section 83(a) of the Code taxes as ordinary income the difference between the amount paid for the Common Stock and the fair market value of the Common Stock as of the date any restrictions
on the Common Stock lapse. In this context, “restriction” includes the right of the Company to buy back the Common Stock pursuant to the Repurchase Option set forth above. Purchaser understands that Purchaser may elect to be taxed at the
time the Common Stock is purchased, rather than when and as the Repurchase Option expires, by filing an election under Section 83(b) (an “83(b) Election”) of the Code with the Internal Revenue Service within 30 days of
the date of purchase, a copy of which is included as Exhibit D. Even if the fair market value of the Common Stock at the time of the execution of this Agreement equals the amount paid for the Common Stock, the 83(b) Election must be made to avoid
income under Section 83(a) in the future. Purchaser acknowledges that the foregoing is only a summary of the effect of United States federal income taxation with respect to purchase of the Common Stock hereunder, and does not purport to be
complete. Purchaser further acknowledges that the Company has directed Purchaser to seek independent advice regarding the applicable provisions of the Code, the income tax laws of any municipality, state or foreign country in which Purchaser may
reside, and the tax consequences of Purchaser’s death. Purchaser assumes all responsibility for filing an 83(b) Election and paying all taxes resulting from such election or the lapse of the restrictions on the Common Stock. 

12.    REFUSAL TO TRANSFER. The
Company shall not be required (a) to transfer on its books any shares of Common Stock of the Company which shall have been transferred in violation of any of the provisions set forth in this Agreement, or (b) to treat as owner of such
shares or to accord the right to vote as such owner or to pay dividends to any transferee to whom such shares shall have been so transferred. 

13.    INSPECTION RIGHTS. Purchaser further
acknowledges and agrees that, except for such information as required to be delivered to Purchaser by the Company pursuant to the Option or the Plan (if any), Purchaser will have no right to receive any information from the Company by virtue of the
grant of the Option or the purchase of shares of Common Stock through exercise of the option, ownership of such shares of Common Stock, or as a result of my being a holder of record of stock of the Company. Without limiting the foregoing, to the
fullest extent permitted by law, Purchaser hereby waives all inspection rights under Section 220 of the Delaware General Corporation Law and all such similar information and/or inspection rights that may be provided under the law of any
jurisdiction, or any federal, state or foreign regulation, that are, or may become, applicable to the Company or the Company’s capital stock (the “Inspection Rights”). Purchaser hereby covenants and agrees never to
directly or indirectly commence, voluntarily aid in any way, prosecute, assign, transfer, or cause to be commenced any claim, action, cause of action, or other proceeding to pursue or exercise the Inspection Rights. 

14.    MISCELLANEOUS. 

(a)    Notices. All notices required or permitted hereunder shall be in writing and shall be deemed
effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed facsimile if sent during normal business hours of the recipient, and if not during normal business hours of the recipient, then on the
next business day, (iii) five calendar days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (iv) one business day after deposit with a nationally recognized overnight courier,
specifying next day delivery, with written verification of receipt. All communications shall be sent to the other party hereto at such party’s address hereinafter set forth on the signature page hereof, or at such other address as such party
may designate by 10 days advance written notice to the other party hereto. 
 (b)    Successors and Assigns.
This Agreement shall inure to the benefit of the successors and assigns of the Company and, subject to the restrictions on transfer herein set forth, be binding upon Purchaser, Purchaser’s successors, and assigns. The Company may assign the
Repurchase Option hereunder at any time or from time to time, in whole or in part. 

 (c)    Attorneys’ Fees; Specific Performance.
Purchaser shall reimburse the Company for all costs incurred by the Company in enforcing the performance of, or protecting its rights under, any part of this Agreement, including reasonable costs of investigation and attorneys’ fees. It is
the intention of the parties that the Company, upon exercise of the Repurchase Option and payment for the shares repurchased, pursuant to the terms of this Agreement, shall be entitled to receive the Common Stock, in specie, in order to have
such Common Stock available for future issuance without dilution of the holdings of other stockholders. Furthermore, it is expressly agreed between the parties that money damages are inadequate to compensate the Company for the Common Stock and that
the Company shall, upon proper exercise of the Repurchase Option, be entitled to specific enforcement of its rights to purchase and receive said Common Stock. 

(d)    Governing Law; Venue. This Agreement shall be governed by and construed in accordance with the laws
of the State of Delaware. The parties agree that any action brought by either party to interpret or enforce any provision of this Agreement shall be brought in, and each party agrees to, and does hereby, submit to the jurisdiction and venue of, the
appropriate state or federal court for the district encompassing the Company’s principal place of business. 

(e)    Further Execution. The parties agree to take all such further action(s) as may reasonably be
necessary to carry out and consummate this Agreement as soon as practicable, and to take whatever steps may be necessary to obtain any governmental approval in connection with or otherwise qualify the issuance of the securities that are the subject
of this Agreement. 
 (f)    Independent Counsel. Purchaser acknowledges that this Agreement has been
prepared on behalf of the Company by Cooley LLP, counsel to the Company and that Cooley LLP does not represent, and is not acting on behalf of, Purchaser. Purchaser has been provided with an opportunity to consult with Purchaser’s own counsel
with respect to this Agreement. 
 (g)    Entire Agreement; Amendment. This Agreement constitutes the
entire agreement between the parties with respect to the subject matter hereof and supersedes and merges all prior agreements or understandings, whether written or oral. This Agreement may not be amended, modified or revoked, in whole or in part,
except by an agreement in writing signed by each of the parties hereto. 
 (h)    Severability. If one or
more provisions of this Agreement are held to be unenforceable under applicable law, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such
provision, then (i) such provision shall be excluded from this Agreement, (ii) the balance of the Agreement shall be interpreted as if such provision were so excluded and (iii) the balance of the Agreement shall be enforceable in
accordance with its terms. 
 (i)    Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with
the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all
purposes. 

 The parties hereto have executed this Agreement as of
                    . 
  

					
	COMPANY:
	
	ALLOGENE THERAPEUTICS, INC.
		
	By:	 	  

		 	Name:	 	  

		 	Title:	 	  

		
	Email:	 	  

	
	PURCHASER:
	
	  

	(Signature)
	
	  

	Name (Please Print)
	
	  

	 Email

			
	  
 ATTACHMENTS:

		
	Exhibit A	  	Notice of Exercise
	Exhibit B	  	Assignment Separate from Certificate
	Exhibit C	  	Joint Escrow Instructions
	Exhibit D	  	Form of 83(b) Election

 [SIGNATURE PAGE TO EARLY EXERCISE
STOCK PURCHASE AGREEMENT] 

 EXHIBIT A 

NOTICE OF EXERCISE 

 ALLOGENE THERAPEUTICS, INC. 

NOTICE OF EXERCISE 

Allogene Therapeutics, Inc. 
 210 East Grand Avenue 

South San Francisco, CA 94080 
 Date of Exercise:
                     
 This constitutes
notice to ALLOGENE THERAPEUTICS, INC. (the “Company”) under my stock option that I elect to purchase the below number of shares of Common Stock of the Company
(the “Shares”) for the price set forth below. 
  

									
	Type of option (check one):	  	 	Incentive ☐	 	  	 	Nonstatutory ☐	 
			
	Stock option dated:	  	 	                        	 	  	 	                        	 
			
	Number of Shares as to which option is exercised:	  	 	                        	 	  	 	                        	 
			
	Certificates to be issued in name of:	  	 	                        	 	  	 	                        	 
			
	Total exercise price:	  	 	$                    	 	  	 	$                    	 
			
	Cash payment delivered herewith:	  	 	$                    	 	  	 	$                    	 

 By this exercise, I agree (i) to provide such additional documents as you may require pursuant to the
terms of the Amended and Restated 2018 Equity Incentive Plan, (ii) to provide for the payment by me to you (in the manner designated by you) of your withholding obligation, if any, relating to the exercise of this option, and (iii) if this
exercise relates to an incentive stock option, to notify you in writing within 15 days after the date of any disposition of any of the Shares issued upon exercise of this option that occurs within two years after the date of grant of this option or
within one year after such Shares are issued upon exercise of this option. 
 I further agree that this Notice of Exercise may be delivered
via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and shall be deemed to have been
duly and validly delivered and be valid and effective for all purposes. 
 I hereby make the following certifications and representations
with respect to the number of Shares listed above, which are being acquired by me for my own account upon exercise of the option as set forth above: 

I acknowledge that the Shares have not been registered under the Securities Act of 1933, as amended (the “Securities
Act”), and are deemed to constitute “restricted securities” under Rule 701 and Rule 144 promulgated under the Securities Act. I warrant and represent to the Company that I have no present intention of distributing or selling
said Shares, except as permitted under the Securities Act and any applicable state securities laws. I further acknowledge that I will not be able to resell the Shares for 

 
at least 90 days after the stock of the Company becomes publicly traded (i.e., subject to the reporting requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934)
under Rule 701 and that more restrictive conditions apply to affiliates of the Company under Rule 144. 
 I further acknowledge and agree
that, except for such information as required to be delivered to me by the Company pursuant to the option or the Plan (if any), I will have no right to receive any information from the Company by virtue of the grant of the option or the purchase of
shares of Common Stock through exercise of the option, ownership of such shares of Common Stock, or as a result of my being a holder of record of stock of the Company. Without limiting the foregoing, to the fullest extent permitted by law, I hereby
waive all inspection rights under Section 220 of the Delaware General Corporation Law and all such similar information and/or inspection rights that may be provided under the law of any jurisdiction, or any federal, state or foreign regulation,
that are, or may become, applicable to the Company or the Company’s capital stock (the “Inspection Rights”). I hereby covenant and agree never to directly or indirectly commence, voluntarily aid in any way, prosecute,
assign, transfer, or cause to be commenced any claim, action, cause of action, or other proceeding to pursue or exercise the Inspection Rights. 

I further agree that, if required by the Company (or a representative of the underwriters) in connection with the first underwritten
registration of the offering of any securities of the Company under the Securities Act, the Shares may be subject to certain transfer restrictions during the Lock-Up Period as provided in Section 8 of the
Option Terms and Conditions. I further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give further effect thereto.
In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to securities subject to the foregoing restrictions until the end of such period. 

I further acknowledge that all certificates representing any of the Shares subject to the provisions of the option shall have endorsed thereon
appropriate legends reflecting the foregoing limitations, as well as any legends reflecting restrictions pursuant to the Company’s Certificate of Incorporation, Bylaws and/or applicable securities laws. 

 

					
		 	                  Very truly yours,
		 		 	  

		 		 	(Signature)
			
		 		 	                                     
                             
		 		 	 Name (Please Print)

		
	Address of Record:	 	                                     
                             
		 	                                     
                             
		 	                                     
                             
			
		 	Email:	 	  

 EXHIBIT B 

STOCK ASSIGNMENT SEPARATE FROM CERTIFICATE 

FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers unto
ALLOGENE THERAPEUTICS, INC., a Delaware corporation (the “Company”), pursuant to the Repurchase Option under that certain Early Exercise Stock Purchase Agreement, dated
[                    ], by and between the undersigned and the Company (the “Agreement”)
                     shares of Common Stock of the Company standing in the undersigned’s name on the books of the Company represented by
Certificate No[s]                      and does hereby irrevocably constitute and appoint both the Company’s Secretary and the Company’s
attorney, or either of them, to transfer said stock on the books of the Company with full power of substitution in the premises. This Assignment may be used only in accordance with and subject to the terms and conditions of the Agreement, in
connection with the repurchase of shares of Common Stock issued to the undersigned pursuant to the Agreement, and only to the extent that such shares remain subject to the Company’s Repurchase Option under the Agreement. 

 

			
	Dated:	 	                    
		 	(leave blank)

  

	
	  

	 (Signature)
  

	  

	Name (Please Print)

 INSTRUCTION: Please do not fill in any blanks other than the signature line. Do not fill
in the date line. The purpose of this Assignment is to enable the Company to exercise its Repurchase Option set forth in the Agreement without requiring additional signatures on the part of Purchaser. 

 EXHIBIT C 

JOINT ESCROW INSTRUCTIONS 

            , 20     

Secretary 
 Allogene Therapeutics, Inc. 

 

                          
               

                          
               

                          
               
 Ladies and Gentlemen: 

As Escrow Agent for both Allogene Therapeutics, Inc., a Delaware corporation (“Company”) and the purchaser listed on the
signature page hereto (“Purchaser”), you are hereby authorized and directed to hold the documents delivered to you pursuant to the terms of that certain Early Exercise Stock Purchase Agreement dated as of
                     (“Agreement”), to which a copy of these Joint Escrow Instructions is attached as an Exhibit, in
accordance with the following instructions: 
 1.    In the event Company or an assignee shall elect to exercise
the Repurchase Option set forth in the Agreement, the Company or its assignee will give to Purchaser and you a written notice specifying the number of shares of stock to be acquired and the time for a closing thereunder at the principal office of
the Company. Purchaser and the Company hereby irrevocably authorize and direct you to close the transaction contemplated by such notice in accordance with the terms of said notice. 

2.    At the closing, you are directed (a) to date the stock assignments necessary for the transfer in
question, (b) to fill in the number of shares being transferred, and (c) to deliver the same, together with the certificate evidencing the shares of stock to be transferred, to the Company. 

3.    Purchaser irrevocably authorizes the Company to deposit with you any certificates evidencing shares of stock
to be held by you hereunder and any additions and substitutions to said shares as specified in the Agreement. Purchaser does hereby irrevocably constitute and appoint you as his
attorney-in-fact and agent for the term of this escrow to execute with respect to such securities all documents necessary or appropriate to make such securities
negotiable and complete any transaction herein contemplated, including but not limited to any appropriate filing with state or government officials or bank officials. Subject to the provisions of this paragraph 3, Purchaser shall exercise all rights
and privileges of a stockholder of the Company while the stock is held by you. 
 4.    This escrow shall
terminate and the shares of stock held hereunder shall be released in full upon the exercise or expiration in full of the Repurchase Option, whichever occurs first. 

5.    If at the time of termination of this escrow under Section 4 herein you should have in your possession
any documents, securities, or other property belonging to Purchaser, you shall deliver all of the same to Purchaser and shall be discharged of all further obligations hereunder; provided, however, that if at the time of termination of this escrow
you are advised by the Company that any property subject to this escrow is the subject of a pledge or other security agreement, you shall deliver all such property to the pledgeholder or other person designated by the Company. 

 6.    Except as otherwise provided in these Joint Escrow
Instructions, your duties hereunder may be altered, amended, modified or revoked only by a writing signed by all of the parties hereto. 

7.    You shall be obligated only for the performance of such duties as are specifically set forth herein and may
rely and shall be protected in relying or refraining from acting on any instrument reasonably believed by you to be genuine and to have been signed or presented by the proper party or parties. You shall not be personally liable for any act you may
do or omit to do hereunder as Escrow Agent or as attorney-in-fact for Purchaser while acting in good faith and in the exercise of your own good judgment, and any act
done or omitted by you pursuant to the advice of your own attorneys shall be conclusive evidence of such good faith. 

8.    You are hereby expressly authorized to disregard any and all warnings given by any of the parties hereto or
by any other person or entity, excepting only orders or process of courts of law, and are hereby expressly authorized to comply with and obey orders, judgments or decrees of any court. In case you obey or comply with any such order, judgment or
decree of any court, you shall not be liable to any of the parties hereto or to any other person, firm or corporation by reason of such compliance, notwithstanding any such order, judgment or decree being subsequently reversed, modified, annulled,
set aside, vacated or found to have been entered without jurisdiction. 
 9.    You shall not be liable in any
respect on account of the identity, authorities or rights of the parties executing or delivering or purporting to execute or deliver these Joint Escrow Instructions documents or papers deposited or called for hereunder. 

10.    You shall not be liable for the outlawing of any rights under any statute of limitations with respect to
these Joint Escrow Instructions or any documents deposited with you. 
 11.    Your responsibilities as Escrow
Agent hereunder shall terminate if you shall cease to be Secretary of the Company or if you shall resign by written notice to the Company. In the event of any such termination, the Secretary of the Company shall automatically become the successor
Escrow Agent unless the Company shall appoint another successor Escrow Agent, and Purchaser hereby confirms the appointment of such successor as Purchaser’s
attorney-in-fact and agent to the full extent of your appointment. 

12.    If you reasonably require other or further instruments in connection with these Joint Escrow Instructions or
obligations in respect hereto, the necessary parties hereto shall join in furnishing such instruments. 

13.    It is understood and agreed that should any dispute arise with respect to the delivery and/or ownership or
right of possession of the securities held by you hereunder, you are authorized and directed to retain in your possession without liability to anyone all or any part of said securities until such dispute shall have been settled either by mutual
written agreement of the parties concerned or by a final order, decree or judgment of a court of competent jurisdiction after the time for appeal has expired and no appeal has been perfected, but you shall be under no duty whatsoever to institute or
defend any such proceedings. 
 14.    All notices required or permitted hereunder shall be in writing and shall
be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed telex or facsimile if sent during normal business hours of the recipient, and if not during normal business hours of the
recipient, then on the next business day, (c) five (5) calendar days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) business day after deposit with a nationally recognized
overnight courier, specifying next day delivery, with written 

  
 2. 

 
verification of receipt. All communications shall be sent to the other party hereto at such party’s address set forth below, or at such other address as such party may designate by ten
(10) days advance written notice to the other party hereto. 
  

					
	Company:	  	Allogene Therapeutics, Inc.	  	
			
		  	  
	  	
		  	  
	  	
		  	  
	  	
		  	Attn: Chief Executive Officer	  	
			
	Purchaser:	  	  
	  	
		  	  
	  	
		  	  
	  	
			
	Escrow Agent:	  	Allogene Therapeutics, Inc.	  	
			
		  	  
	  	
		  	  
	  	
		  	  
	  	
		  	Attn: Secretary	  	

 15.    By signing these Joint Escrow Instructions, you become a party hereto only
for the purpose of said Joint Escrow Instructions; you do not become a party to the Agreement. 
 16.    You
shall be entitled to employ such legal counsel and other experts (including, without limitation, the firm of Cooley LLP) as you may deem necessary properly to advise you in connection with your obligations hereunder. You may rely upon the advice of
such counsel, and you may pay such counsel reasonable compensation therefor. The Company shall be responsible for all fees generated by such legal counsel in connection with your obligations hereunder. 

17.    This instrument shall be binding upon and inure to the benefit of the parties hereto and their respective
successors and permitted assigns. It is understood and agreed that references to “you” and “your” herein refer to the original Escrow Agents and to any and all successor Escrow Agents. It is understood and agreed that the Company
may at any time or from time to time assign its rights under the Agreement and these Joint Escrow Instructions in whole or in part. 

[Remainder of page intentionally left blank] 

  
 3. 

 18.    These Joint Escrow Instructions shall be governed by and
interpreted and determined in accordance with the laws of the State of Delaware, as such laws are applied by Delaware courts to contracts made and to be performed entirely in Delaware by residents of that state. The parties hereby expressly consent
to the personal jurisdiction of the state and federal courts located in the county in which the Company has its principal offices for any lawsuit arising from or related to this Agreement. 

 
  

							
	Very truly yours,
		
		 	COMPANY:
		
		 	ALLOGENE THERAPEUTICS, INC.
			
		 	By:	 	
                     
                                       

		 		 	Name:	 	
                     
                                       

		 		 	Title:	 	
                     
                                       

		
		 	PURCHASER:
		 	  

		 	(Signature)
		
		 	  

		 	         Name (Please Print)

 ESCROW AGENT: 

 

                         
                                         
   
 DAVID M. TANEN, SECRETARY 

  

[SIGNATURE PAGE TO JOINT ESCROW
INSTRUCTIONS] 

 EXHIBIT D 

83(B) ELECTION FORM AND INSTRUCTIONS FOR
FILING 
 [THIS FORM IS DESIGNED FOR
INDIVIDUAL PURCHASERS. CORPORATE OR TRUST PURCHASERS 

SHOULD CONTACT THEIR TAX PROFESSIONAL TO
REVIEW BEFORE SUBMITTING.] 
 Attached is a form of election under Section 83(b) of
the Internal Revenue Code and an accompanying IRS cover letter. Please fill in your social security number or taxpayer identification number and sign the election and cover letter, then proceed as follows: 

 

	(a)	 Make three copies of the completed election form and one copy of the IRS cover letter.

  

	(b)	 Send the original signed election form and cover letter, the copy of the cover letter, and
a self-addressed stamped return envelope to the Internal Revenue Service Center where you would otherwise file your tax return1. Even if an address for an Internal Revenue Service Center is
already included in the forms below, it is your obligation to verify such address. This can be done by searching for the term “where to file” on www.irs.gov or by calling 1 (800) 829-1040.

 Sending the election via certified mail, requesting a return receipt, with the certified mail number written on the
cover letter is also strongly recommended. 
  

	(c)	 Deliver one copy of the completed election form to Allogene Therapeutics, Inc.. 

 

	(d)	 Applicable state law may require that you attach a copy of the completed election form to your state personal
income tax return(s) when you file it for the year of exercise (assuming you file a state personal income tax return).2 

Please consult your personal tax advisor(s) to determine whether or not a copy of this Section 83(b) election should be filed with your
state personal income tax return(s). 
  

	(e)	 Retain one copy of the completed election form for your personal permanent records. 

 
  

	1	 Note: Per Treasury Regulation § 1.83-2(c), the Section 83(b) election must be filed with the
IRS office where the person otherwise files his or her tax return. As of October 2016, if you live in a foreign country or are a dual status alien (foreigners that will have lived both in their home country and the United States during the year in
which they make the election) you should send the 83(b) election to Austin, TX 73301-0215. You can verify this is still the correct address at:
http://www.irs.gov/uac/Where-to-File-Addresses-for--Taxpayers-and--Tax-Professionals-Filing-Form-1040. 

	2 	 Note: Pursuant to Treasury Regulations finalized in July 2016 (Treas. Reg. § 1.83-2(c); T.D. 9779), taxpayers are no longer required to submit a copy of a Code Sec. 83(b) election with their federal personal income tax returns for the year in which the property subject to the
election was transferred. However, you are strongly encouraged to retain a copy of the completed election form and the IRS filed-stamped copy of your cover letter along with a copy of the federal personal income tax return for the year in which the
property subject to the election was transferred for your personal permanent records in case you ever need to demonstrate proper and timely filing (a common requirement imposed by acquirers in M&A transactions). 

 Note: An additional copy of the completed election form must be delivered to the transferee
(recipient) of the property if the service provider and the transferee are not the same person. 
 Please note that the election must be filed with
the IRS within 30 days of the date of your restricted stock grant. Failure to file within that time will render the election void and you may recognize ordinary taxable income as your vesting restrictions lapse. The Company and its counsel cannot
assume responsibility for failure to file the election in a timely manner under any circumstances. 

 SECTION 83(b) ELECTION 

            , 201     

Department of the Treasury 
 Internal Revenue Service 

[City, State Zip]3 
  

	Re:	 Election Under Section 83(b) of the Code 

Ladies and Gentlemen: 
 The undersigned taxpayer hereby elects,
pursuant to Section 83(b) of the Internal Revenue Code of 1986, as amended, to include in gross income as compensation for services the excess (if any) of the fair market value of the shares described below over the amount paid for those
shares. The following information is supplied in accordance with Treasury Regulation § 1.83-2: 
  

	1.	 The name, social security number, address of the undersigned, and the taxable year for which this election
is being made are: 

 Name:
                                         
                 
 Social Security Number:
                             

Address:                      
                                 

                        
                                         
    
 Taxable year: Calendar year 201    .4 

 

	2.	 The property that is the subject of this election: [#] shares of common stock of Allogene
Therapeutics, Inc., a Delaware corporation (the “Company”). 

  

	3.	 The property was transferred on: [●], 201    . 

 

	4.	 The property is subject to the following restrictions: Some or all of the shares are subject to
forfeiture or repurchase at less than their fair market value if the undersigned does not continue to provide services for the Company for a designated period of time. The risk of forfeiture or repurchase lapses over a specified vesting period.

  

	5.	 The fair market value of the property at the time of transfer (determined without regard to any
restriction other than a nonlapse restriction as defined in Treasury Regulation § 1.83-3(h)): $[●] per share x [#] shares = $[●] 

  

	6.	 For the property transferred, the undersigned paid: $[●] per share x [#] shares = $[●].

  
  

	3 	 Note: Per Treasury Regulation § 1.83-2(c), the Section 83(b) election must be filed with the
IRS office where the person otherwise files his or her tax return. Assuming these are individual taxpayers who would file a Form 1040, see
http://www.irs.gov/uac/Where-to-File-Addresses-for—Taxpayers-and—Tax-Professionals-Filing-Form-1040. Use the address in the row which includes the state in which the service provider lives and in the column entitled “And you
ARE NOT enclosing a payment”. 

	4 	 Note: If an entity is the service provider, instead use “Fiscal year ending
            .” 

	7.	 The amount to include in gross income is:
$[●].5 

 The undersigned taxpayer will file this election with the Internal
Revenue Service office with which taxpayer files his or her annual income tax return not later than 30 days after the date of transfer of the property. A copy of the election also will be furnished to the person for whom the services were performed
and the transferee of the property. Additionally, the undersigned will include a copy of the election with his or her income tax return for the taxable year in which the property is transferred. The undersigned is the person performing the services
in connection with which the property was transferred. 
  

	
	Very truly yours,
	  

	[Name]

  
  

	5 	 Note: This should equal the amount in Item 5 minus the amount in Item 6, and in many cases will
be $0.00. 

 RETURN SERVICE REQUESTED 

Department of the Treasury 
 Internal Revenue Service 

[City, State, ZIP] 
  

	Re:	 Election Under Section 83(b) of the Internal Revenue Code

 Dear Sir or Madam: 

Enclosed please find an executed form of election under Section 83(b) of the Internal Revenue Code of 1986, as amended, filed with
respect to an interest in Allogene Therapeutics, Inc. 
 Also enclosed is a copy of the signed form of election under Section 83(b).
Please acknowledge receipt of these materials by marking the copy when received and returning it in the enclosed stamped, self-addressed envelope. 

Thank you very much for your assistance. 
  

	
	Very truly yours,
	
	  

	[Name]

 Enclosures

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}]]